基于浊毒学说对慢性萎缩性胃炎的临床研究及对胃癌BGC-823细胞株体外实验研究
|
摘要
慢性萎缩性胃炎(chronic atrophic gastritis,CAG)是消化系统的一种常见病,是指炎症导致的胃腺体破坏、减少、萎缩、甚至消失,表面上皮细胞丧失分泌能力,黏膜肌层增厚的病理、临床病症。上世纪40年代Schindle首次提出CAG的概念,1978年WHO将其列为胃癌的癌前疾病或癌前状态(Precancerous conditions),而在CAG基础上伴发的肠上皮化生(Intestinal metaplasia,IM)和异型增生(Dysplasia,Dys),则是胃癌的癌前病变(Precancerous Lesions of Gastric Cancer,PLGC),癌变的发生率较高。CAG及其癌前病变已成为目前研究的重点,及早识别、防治癌前疾病和癌前病变,成为降低胃癌发生率和死亡率行之有效的方法。目前,西医学治疗本病尚缺乏有效的治疗手段。中医药在治疗CAG方面有着明显的优势,其改善患者症状及预防疾病向癌转化等方面的疗效肯定且显著。
中医学将CAG病变归属于“胃脘痛”、“胃痞”、“痞满”、“嘈杂”等病证范畴。导师李佃贵教授认为,随着社会的发展,生活方式、饮食结构的改变,环境因素变化,包括大气污染等,现代人的精神社会压力加大,疾病模式会发生变化。在临床诊疗中观察到许多慢性疾病患者病情反复,缠绵难愈,常有颜面晦浊、暗滞,少泽,大便粘腻不爽,小便黄,舌质暗红,苔黄或黄腻,脉弦滑等脉证表现,李师在总结前人理论的基础上,结合多年的临证经验,提出“浊毒学说”,认为浊毒既是一种对人体脏腑经络及气血阴阳均能造成严重损害的致病因素,同时也是多种病因导致脏腑功能紊乱、气血运行失常,机体内产生的代谢产物不能及时正常排出,蕴积体内而化生的病理产物。其致病特点,(1)粘滞难解易阻遏气机;(2)入血入络易伤气阴;(3)气血失调易瘀易积。浊毒为患所造成的病证,属于浊毒证,是指以浊毒为病因使机体处于浊毒状态从而产生特有临床表现的一组或几组证候群。运用浊毒学说指导CAG治疗,初步取得了较为满意的临床疗效。本研究旨在进一步完善该学说在CAG的证候规律,探讨化浊解毒方药的作用机制。
目前,中医关于CAG的证候分型,行业学会及各家经验存在多种不同的观点,如有肝胃不和、脾胃湿热、湿浊中阻、胃络瘀阻、脾胃虚弱、胃阴不足6个证型分类;有肝胃不和、脾胃虚弱(含虚寒)、脾胃湿热、胃阴不足、胃络瘀阻、脾虚气滞等证型分类;还有的分为气阴两虚,虚火灼胃和脾胃气虚证型等等,繁杂不一,为临床和科研工作带来极大不便。
中医证候学研究是目前中医药研究工作的前沿领域,20年来,随着统计学、流行病学、计量学、模糊数学等诸多学科知识的不断渗透,被用于中医证候诊断标准量化研究的方法也日益增多。聚类分析是将样品个体或变量指标按其具有的特性进行分类的一种多元统计方法,分为样品聚类分析和变量聚类分析,其目的是根据样品或指标间相似程度的大小,将性质相近的归在同一类,而将性质相差比较大的归在不同的类,在中医证候研究中的合理应用能够极大地提高中医辨证的规范性和准确性。
本研究采用聚类分析的方法,分析CAG较大样本病例的临床表现,以期为临床提供较为合理、科学、规范的辨证分型,同时,通过应用本方法来探讨浊毒证的证候规律。
观察CAG浊毒证患者的胃泌素(Gas)、胃动素(MTL)、生长抑素(SS)水平变化,探讨CAG浊毒证证型与胃肠激素之间的相关关系,进一步明确胃肠激素的变化在CAG中医证型中是否有特异性,胃肠激素变化异常是否能导致不同证型临床征象,提高对本证型的认识。
CAG属癌前疾病,CAG伴IM,被认为是萎缩的典型标志以及胃癌的前兆,通过上述分析,发现浊毒内蕴是本病的主要证候特点,为此,创立了化浊解毒方,并观察本方治疗CAG的临床疗效。
通过观察化浊解毒方药及其拆方含药血清对体外培养的人胃癌BGC-823细胞增殖和凋亡的影响,从实验研究方面,进一步探讨化浊解毒方药在防治胃癌前病变中可能的作用机制。
第一部分慢性萎缩性胃炎证候学聚类研究
目的:采用变量聚类分析的方法,对CAG临床资料进行探索性的中医证候分类研究,旨在应用现代数理统计方法探索CAG较为规范的临床证候分型,验证浊毒证候的特点,为临床辨证提供客观依据。
方法:采集河北省中医院消化科门诊及住院CAG患者,所有患者依照西医诊断标准确诊为CAG,符合纳入、排除标准。记录371例CAG患者的症状、体征、舌象和脉象等临床资料,使用SAS软件对56个变量进行3-6类的聚类分析。
结果:确定CAG患者中医证候分为:浊毒内蕴、肝胃不和、胃络瘀阻、脾胃虚弱、胃阴不足5类,其解释比例为72.74%,并初步确定了各证候诊断的主症、次症。浊毒内蕴证诊断:主症:畏寒肢冷,胃脘隐痛,苔黄、厚、腻,脉细、滑;次症:胸闷,胁胀痛,口臭,脉沉、缓。肝胃不和证诊断:主症:胃脘胀满,嗳气,脉弦;次症:嘈杂,反酸,易怒,饮食减少,嗳腐吞酸。胃络瘀阻证诊断:主症:胃脘刺痛,拒按,面色暗滞,脉涩;次症:恶心,舌有瘀点、瘀斑,苔薄。脾胃虚弱证诊断:主症:胃脘痞满,气短,便溏,舌有齿痕;次症:面色萎黄,腹痛欲泻,乏力,舌淡,脉弱。胃阴不足证诊断:主症:胃脘胀痛,苔少或无,舌少津,舌有裂纹,大便干,脉数;次症:口干,失眠,脉迟。
小结:应用变量聚类分析,同时结合临床专家意见,能够帮助进行CAG中医证候的合理分类,并对提出的CAG新的证候类型—浊毒内蕴证进行了较为规范、科学的验证,为中医辨证论治CAG提供一定较为合理、科学的理论依据。
第二部分慢性萎缩性胃炎浊毒证与胃肠激素相关性研究
目的:本研究旨在通过探讨CAG浊毒证与胃肠激素分泌变化规律相关性研究,以揭示CAG浊毒证患者胃肠激素的分泌特点,提高对浊毒证的认识,为临床诊治提供客观指标方面的依据。
方法:采集河北省中医院2006年12月-2007年12月消化科门诊及住院的CAG患者50例,所有患者据符合西医诊断标准和中医辨证诊断标准,分为浊毒证组25例和脾虚证组25例,同时选取健康志愿者设立健康对照组25例。采用放射免疫法检测患者血浆胃泌素(Gas)、胃动素(MTL)、生长抑素(SS)的含量。
结果:
1血浆Gas水平
与健康组比较,CAG浊毒证组患者血浆Gas水平无明显变化,两组之间比较,差异无统计学意义(104.82±47.91 pg/ml VS 100.19±48.76 pg/ml, P>0.05)。
与健康组比较,CAG脾虚证组患者血浆Gas水平均下降明显,两组之间比较,差异有统计学意义(79.17±34.02 pg/ml VS 100.19±48.76 pg/ml, P<0.05)。
与CAG脾虚证组比较,CAG浊毒证组患者血浆Gas水平较高,两组之间比较,差异有统计学意义(104.82±47.91pg/ml VS 79.17±34.02 pg/ml, P<0.05)。
2血浆MTL水平
与健康组比较,CAG浊毒证组患者血浆MTL水平无明显变化,两组之间比较,差异无统计学意义(302.89±126.82 pg/ml VS 326.00±58.76 pg/ml, P>0.05)。
与健康组比较,CAG脾虚证组患者血浆MTL水平下降明显,两组之间比较,差异有统计学意义(208.72±85.21 pg/ml VS 326.00±58.76 pg/ml, P<0.05)。
与CAG脾虚证组比较,CAG浊毒证组患者血浆MTL水平较高,两组之间比较,差异有统计学意义(302.89±126.82pg/ml VS 208.72±85.21 pg/ml, P<0.05)。
3血浆SS水平
与健康组比较,CAG浊毒证组患者血浆SS水平无明显变化,两组之间比较,差异无统计学意义(11.81±6.34 pg/ml VS 10.10±7.20 pg/ml, P>0.05)。
与健康组比较,CAG脾虚证组患者血浆SS水平下降不明显,两组之间差异无统计学意义(10.95±6.87 pg/ml VS 10.10±7.20 pg/ml, P>0.05)。与CAG脾虚证组比较,两组血浆SS水平之间,差异无统计学意义(11.81±6.34pg/ml VS 10.95±6.87 pg/ml, P>0.05)。
小结:
1在CAG浊毒证患者中,血浆Gas、MTL的变化有证型特异性。
2血浆Gas、MTL的变化可能导致不同证型临床征象。
第三部分化浊解毒方治疗慢性萎缩性胃炎临床研究
目的:本文旨在通过观察化浊解毒方对CAG患者的症状积分、胃镜像、病理学、Hp等方面的影响,探讨该方治疗CAG的临床疗效。
方法:收集河北省中医院消化科门诊及住院的CAG患者共92例,随机分为治疗组和对照组,治疗组口服化浊解毒方治疗,1袋/次,2次/日,早、晚空腹温服。对照组口服中成药胃复春4片/次,3次/日。12周为1个疗程,连用2个疗程。
结果:
1两组临床疗效比较:治疗组52例中临床痊愈17例,显效21例,有效11例,无效3例,总有效率94.23%;对照组40例中临床痊愈7例,显效10例,有效8例,无效15例,总有效率62.5%。两组临床疗效比较,差异有统计学意义(P<0.01)。
2两组主要症状积分比较:两组治疗后胃痛、痞满、嗳气、纳差、乏力等症状积分明显减少,差异有统计学意义(治疗组:1.32±0.51 VS 4.82±1.25 P <0.01;对照组:1.58±0.65 VS 4.69±1.17, P <0.01);治疗后,治疗组症状积分明显低于对照组,与对照组比较,差异有统计学意义(1.32±0.51 VS 1.58±0.65, P<0.05)。
3两组胃镜疗效比较:治疗组胃镜结果显示在胃黏膜充血、糜烂、黏膜白象、黏膜粗糙、血管透见方面的疗效优于对照组,两组比较,差异有统计学意义(治疗组总有效率分别为86.96%、92%、64.58%、71.42%、65.63%,对照组总有效率分别为60%、78.95%、38.23%、36.36%、31.82%,P<0.05或P<0.01)。治疗组和对照组改善胃黏膜水肿的比较,差异无统计学意义(治疗组总有效率为87.5%、对照组总有效率71.88%,P>0.05)。
4两组病理疗效比较:治疗组在改善胃黏膜萎缩,肠上皮化生(IM)总有效率分别为78.85%、84.62%,对照组总有效率分别为52.5%、55%,治疗组明显优于对照组,两组比较,差异有统计学意义(P<0.01)。
5两组抗Hp感染疗效比较:治疗组和对照组抗Hp感染的根除率分别为47.22%和44.44%,两组的根除率比较,差异无统计学意义(P>0.05)。
6安全性指标检测:患者治疗前后血、尿、便常规及肝、肾功能和心电图的均无异常改变。
小结:
1化浊解毒方能够较好改善CAG患者的临床症状。
2化浊解毒方对胃黏膜的恢复、肠上皮化生的改善有较好疗效。
3化浊解毒方有一定的抗Hp感染作用。
第四部分化浊解毒方药及其拆方含药血清对人胃癌BGC-823细胞增殖和凋亡的影响
目的:本课题旨在通过观察化浊解毒方药及其拆方含药血清对人胃癌BGC-823细胞增殖和凋亡的影响,探讨该方药是否通过抑制细胞增殖作用机制,预防CAG癌前病变,为该方药临床应用提供实验依据。
方法:
1含药血清的制备:SD大鼠,雄性,随机分为4组:空白对照组、化浊解毒方组、化浊方组、解毒方组。实验组分别按345.9g·kg~(-1)·d~(-1)、208.4g·kg~(-1)·d~(-1)、137.3g·kg~(-1)·d~(-1)剂量灌胃,空白对照组2ml生理盐水灌胃,1次/日,共3次。末次给药后2h,常规分离血清保存。
2给药及分组:分别以各组的含药血清对胃腺癌BGC-823细胞进行干预,分为空白对照组、化浊解毒方组、化浊方组、解毒方组4组。
3检测指标:分别采用MTT、流式细胞术、免疫组化法检测不同含药血清对BGC-823细胞的生长抑制、细胞周期和凋亡率的影响及BGC-823细胞中Bcl-2、Bax蛋白的表达。
结果:
1细胞增殖抑制实验:与空白对照组比较,化浊解毒方、化浊方、解毒方,均对BGC-823细胞有抑制作用(P<0.05或P<0.01),抑制率分别为39.3%、16.5%、16.8%。尤以化浊解毒方效果显著,其抑制作用强于化浊方和解毒方(P<0.01),而化浊方组与解毒方组之间比较,差异无统计学意义(P>0.05)。
2 FCM对BGC-823细胞的细胞周期检测结果:与空白对照组比较,经化浊解毒方处理的BGC-823细胞的细胞周期发生明显变化,G0/G1期细胞明显增多(P<0.01),S期细胞比率显著下降(P<0.01),G2/M期无明显变化(P>0.05),多数细胞阻滞在G0/G1期。而化浊方、解毒方对BGC-823细胞的细胞周期无明显影响(P>0.05)。
3 FCM对BGC-823细胞凋亡率的检测结果
BGC-823细胞经不同含药血清处理48h后,DNA直方图上出现典型的亚二倍体凋亡峰。FCM结果显示:化浊解毒方组、化浊方组、解毒方组凋亡率分别为(16.85±0.63)%、(11.48±0.50)%,(12.38±0.60)%,与空白对照组(2.09±0.25)%比较,差异均有统计学意义(P<0.01);与化浊解毒方比较,化浊方组、解毒方组凋亡率有统计学意义(P<0.01);化浊方组与解毒方组比较,差异无统计学意义(P>0.05)。
4免疫组化检测Bcl-2、Bax蛋白表达
BGC-823细胞经化浊解毒方、化浊方、解毒方含药血清干预48h后,Bcl-2蛋白阳性表达率均明显降低,分别为(29.73±4.34)%、(41.63±6.47)%、(37.11±4.63)%,与空白对照组(53.74±2.97)%比较,差异均具有统计学意义(P<0.01)。化浊方组、解毒方组与化浊解毒方组比较,差异有统计学意义(P<0.01),而化浊方与解毒方两组比较,差异无统计学意义(P>0.05)。
Bax蛋白阳性表达率均显著升高,化浊解毒方组、化浊方组、解毒方组阳性表达率分别为(58.11±4.19)%、(32.25±2.93)%、(34.84±2.66)%,与空白对照组(25.17±2.36)%比较,差异均有统计学意义(P<0.01)。化浊方组、解毒方组与化浊解毒方比较,差异有统计学意义(P<0.01),而解毒方与化浊方两组比较,差异无统计学意义(P>0.05)。
5流式细胞术检测Bcl-2、Bax蛋白表达
流式细胞仪检测结果显示,与空白对照组比较,化浊解毒方、化浊方、解毒方作用于胃癌BGC-823细胞48h后,Bcl-2蛋白表达均明显降低,具有统计学意义(257.67±9.02 VS 330.22±7.13;291.22±11.07 VS 330.22±7.13;276.20±9.10 VS 330.22±7.13 ,P均<0.01);细胞内Bax蛋白表达水平均增高,具有统计学意义(330.14±8.19 VS 281.23±12.71,P<0.01;303.84±6.60 VS 281.23±12.71, P<0.05;310.54±13.29 VS 281.23±12.71,P<0.01)。
Bcl-2蛋白和Bax蛋白表达水平,与化浊解毒方组比较,解毒方组、化浊方组差异均有统计学意义(分别为P<0.01,P<0.05);解毒方组与化浊方组比较,差异无统计学意义(P>0.05)。
小结:
1化浊解毒方可抑制人胃腺癌BGC-823细胞增殖,其作用机制可能与其干扰细胞周期,诱导细胞凋亡有关。
2化浊解毒方及其拆方发挥诱导凋亡作用的机制可能是通过上调促凋亡蛋白Bax的表达,下调凋亡抑制蛋白Bcl-2的表达来实现的。
3化浊方、解毒方均能诱导细胞凋亡,而对细胞周期无影响。经两者配伍后的化浊解毒方不仅能诱导细胞凋亡,而且能将细胞阻滞于G0/G1期,因此其对胃腺癌BGC-823细胞抑制增殖作用明显增强。
结论:
1应用变量聚类分析,能够帮助进行CAG中医证候的合理分类,并探讨CAG浊毒证证候特点,为中医辨证论治CAG提供一定较为合理、科学的理论依据。
2在CAG浊毒证患者中,血清Gas、MTL的变化有证型特异性。血浆Gas、MTL的变化可能导致不同证型临床征象。
3化浊解毒方药能够较好的改善CAG患者的临床症状,对胃黏膜的恢复、肠上皮化生的改善亦有较好疗效,并且有一定的抗Hp感染作用。
4化浊解毒方及其拆方含药血清对人胃癌BGC-823细胞增殖产生抑制作用,促进BGC-823细胞的凋亡,可能是该类方药预防胃癌及逆转癌前病变作用机制之一。
Chronic atrophic gastritis(CAG) is a common disease of digestive system. Its pathological changes was caused by inflammation, such as the destruction, reduce, shrink or even disappear of gastric glands, the loss of surface epithelial cell secretion capacity and mucosal thickening of the muscle. The last century 40's, Schindle first proposed the concept of CAG. WHO would be the CAG as a precancerous lesion of gastric cancer in 1978, CAG associated with intestinal metaplasia and dysplasia are precancerous lesions of gastric cancer. The possibility of cancer is larger. CAG and its precancerous lesions has become the focus of the study. Early detection, prevention and treatment of precancerous diseases and precancerous lesions, become a effective way of lower incidence and mortality of gastric cancer.The application of traditional Chinese medicine(TCM) in the treatment of chronic atrophic gastritis has a distinct advantage, the improvement of patient symptoms and to correct the effect of disease and so on, it is affirmative and significant.
CAG disease would be attributed to "Epigastralgia, gaster-mass, consumptive disease" syndrome in TCM. Professor Diangui Li thinks that modern people’s pressure of spirit and society become larger and disease patterns will changes with the development of society, lifestyle and diet changes. We observed many patients with chronic diseases that their conditions were repeated and refractory lingering in the clinical treatment.They had several clinical manifestations,such as dark cloud complexion, dark stagnation and less burnish, sticking and greasy stool, yellow urine, dark red body of the tongue, surname or greasy coated tongue, slippery pulse and so on. Professor Diangui Li introduced Zhuodu theory in the base of summarizing predecessor’s theory combined with years of clinical experience .He think Zhuodu is one of pathopoiesis factors which can cause serious harm on the human entrails and meridian and the QI-blood of yin and yang. Meanwhile, it’s the pathological products came from metabolic products which accumulated in the body when it’s entrails functional disorders and QI-blood circulation is not normal.Three pathogenic characteristics of Zhuodu: (1)Zhuodu is hard to dissolve and easy inducing disorder of vital energy.(2) Zhuodu is easy entering blood and collaterals and inducing disorder of vital energy.(3) Zhuodu is easy inducing incoordination between vital energy and blood and forming blood stasis. The symptoms caused by Zhuodu belong to Zhuodu Zheng. It refers to a group or several groups of syndromes group which have specific clinical manifestations when the body is in the state of Zhuodu caused by Zhuodu.We have obtained a relatively satisfactory clinical efficacy applying Zhuodu theory in the treatment of CAG. The study aims at consummating further the symptoms law of the theory in CAG and exploring the mechanism of Huazhuojiedu prescription.
At present, it is discordant that the viewpoint of many institute and medical scientist about the typing of CAG in TCM. Some Chinese medical scientist consider that the typing of CAG is GanWeiBuHe, PiWeiShiRe, ShiZhuoZhongZu, WeiLuoYuZu, PiWei XuRuo, WeiYingBuZu. But other Chinese medical scientist considered that the typing of CAG is GanWeiBuHe, PiWeiXuRuo, PiWeiShiRe, WeiYingBuZu, WeiLuoYuZu, PiXuQiZhi. At the same time, some Chinese medical scientist consider that the typing of CAG is QiYing LiangXu, XuHuoZuo Wei, PiWeiQiXu. The discrepancy about the typing of CAG in TCM increase difficulty in evolving clinical work and scientific research.
The study about the symptom of TCM is the frontline of the research on TCM. Over 20 years, the investigative methods of quantizating applicated in studying on diagnostic criteria of Chinese medical symptom are increasing along with the permeating of the knowledge of statistics, epidemiology, metrology, vague mathematics and so on. Cluster analysis is one kind of multivariant statistical method whice can sort the sample or variables index to sample cluster analysis or variables cluster analysis according to theirs characteristics. Cluster analysis aims to classify those samples or variables index whice have similar character into one sort according to the similar degree among the samples or variables indexs. Reasonable application of cluster analysis in study on Chinese medical symptom can enormously raise specification and accuracy rating of differentiation of symptoms and signs in TCM.
In this study, we have adopted the way of cluster analysis to analysis of large sample of cases of clinical manifestations and aim to provide reasonable scientific and normative differentiation of symptoms and signs for classification of syndrome for clinical, to investigate the regularity of symptoms and signs of Zhuodu Zheng.
We tried to explore correlativity of the Zhuodu Zheng with the gut hormones by observing the change of the level of Gas, MTL and SS in patients of CAG and definite if the change of the level of gut hormones have variability in different type of syndrome of TCM, and if the abnormal content of gut hormones can lead different type of syndrome. The study can elevate our recognition about the Zhuodu Zheng of CAG.
CAG is a kind of premalignant disease. CAG combining IM was known as atrophic typical indicate and gastric carcinomatous premonition. Through above-mentioned analysis, it was discovered that Zhuodu NeiYun was the principal characteristic of symptom of CAG, so we formulated HuaZhuoJieDu decoction and observed the curative effect of Huazhuo Jiedu decoction on treating CAG combining IM.
At experimental point of view, we explored the possible mechanism of Huazhuo Jiedu to prevent and cure gastric carcinomatous precancerosis by observing the effect of Huazhuo Jiedu and their separate Huazhuo Jiedu decoction containing serum on proliferation and apoptosis of cultured human gastric cancer BGC-823 cell in vitro.
Part 1: Study on Symptoms of Chronic atrophic gastritis in Traditional Chinese medicine by the way of Cluster analysis
Objective:The study on the clinical data of CAG probed the regularity of different type of syndrome of TCM of CAG by the way of Cluster analysis. The study aims at exploring normative typing of syndrome of TCM of CAG and providing objective evidence for clinical differentiation of symptoms and signs by the way of modern mathematical statistics.
Methods: The 371 patients visiting the clinic service or being in hospital at the Medical Department of Digestion of TCM Hospital of Hebei Province were diagnosed CAG according to the diagnostic criteria in modern medicine. Those patients are accordance with the criteria of internalizing and removing. The sysptoms,physical sign, tongues demonstration and pulse tracings of the 371 patients of with CAG were collected and recorded. We did Cluster analysis by SAS software for 56 variables through sorting 3-6 types.
Results: The syndromes of these CAG Patients could be divided into 5 types: ZhuoDuNeiYun, GanWeiBuHe, WeiLuoYuZu, PiWeiXuRuo, WeiYing BuZu. The proportion explained was 72.74%. The principal and minor symptom of each type of syndromes of these CAG initially definited. The diagnostic criteria of ZhuoDuNeiYunZheng: the principal symptom and sign: chilly and cold limbs, stomachache, yellow thick and greasy fur,samll and smooth pulse; the minor symptom and sign: full sensation in the chest, distending pain over hypochondrium, halitosis, sunken pulse, even and soft pulse. The diagnostic criteria of GanWeiBuHeZheng: the principal symptom and sign: distention of stomach, eructation, wiry pulses; the minor symptom and sign: gastric upset, sour regurgitation, ill-temper, anorexia, eructation with foul odour and acidr regurgitation. The diagnostic criteria of WeiLuoYuZuZheng: the principal symptom and sign: prickle of stomach and tenderness, dimmish blackish complexion ,unsmooth pulses; the minor symptom and sign: nausea, tongue with ecchymosis, thin fur;The diagnostic criteria of PiWeiXu RuoZheng: the principal symptom and sign:felling of fulless and oppression, shortness of breath, loose stool, tongue with teeth marks on its margin; the minor symptom and sign:s,allow complexion, abdominal pain, acratia, pale tongue, weak pulse. The diagnostic criteria of WeiYing BuZuZheng: the principal symptom and sign: distending pain of stomach, tongue without fur, fissuared tongue, constipation, ripid pulses; the minor symptom and sign: dry mouth, sleepessness, slow pulse.
Conclusions: The way of variable cluster analysis combined with the opinions of clinical expert could help us do reasonable syndrome differentiation for CAG patients. Meanwhile, ZhuoDuNeiYunZheng was inspected and verified rationally and scientifically as one new type of syndrome of CAG by the study. The study provides certain reasonable and scientific theoretical foundation for CAG on selection of treatment based on the differential diagnosis.
Part 2: Study on dependablity of Zhuo Du Zheng of Chronic Atrophic Gastritis with Gut Hormone
Objective: The study aims to reveal the characteristic of gut hormone secretion of the patient of CAG Zhuo Du Zheng and to provid objective evidence on indicatrix by investigating the dependablity of Zhuo du zheng with the changing of gut hormone.
Methods: 50 patients who visited the Medical Department of Digestion of Traditional Chinese Medicine Hospital of Hebei Province between December, 2006 and December, 2007 were diagnosed CAG according to diagnostic criteria in modern medicine. Those patients who lived up to the criteria to internalize were divided into Zhuo Du group and Pi Xu group according to diagnostic criteria in Traditional Chinese Medicine. Healthy normal group also were composed of 25 healthy volunteers. The number of people in three groups all was 25.The level of gastrin, motilin and somatostatin in blood plasma were detected by radio-immunifaction.
Results:
1 The level of Gas in blood plasma
Compared with normal group, the level of gastrin in blood plasma of Zhuodu group didn't have marked change, there wasn't statistical significance between two groups(104.82±47.91 pg/ml VS 100.19±48.76 pg/ml, P>0.05).
Compared with normal group, the level of gastrin in blood plasma of Pixu group remarkably decreased. There was statistical significance between two groups(79.17±34.02 pg/ml VS 100.19±48.76 pg/ml, P<0.05).
Compared with Pi Xu group, the level of gastrin in blood plasma of Zhuodu group was higher. There was statistical significance between two groups(104.82±47.91pg/ml VS 79.17±34.02 pg/ml, P<0.05).
2 The level of MTL in blood plasma
Compared with normal group, the level of motilin in blood plasma of Zhuodu group didn't have marked change, there wasn’t statistical significance between two groups(302.89±126.82 pg/ml VS 326.00±58.76 pg/ml, P>0.05).
Compared with normal group, the level of motilin in blood plasma of Pixu group remarkably decreased. There was statistical significance between two groups(208.72±85.21 pg/ml VS 326.00±58.76 pg/ml, P<0.05).
Compared with Pixu group, the level of motilin in blood plasma of Zhuodu group was higher. There was statistical significance between two groups(302.89±126.82pg/ml VS 208.72±85.21 pg/ml, P<0.05).
3 The level of SS in blood plasma
Compared with normal group, the level of somatostatin in blood plasma of Zhuodu group didn't have marked change, there wasn't statistical significance between two groups(11.81±6.34 pg/ml VS 10.10±7.20 pg/ml, P>0.05).
Compared with normal group, the level of somatostatin in blood plasma of Pixu group didn't decreased. There wasn't statistical significance between two groups(10.95±6.87 pg/ml VS 10.10±7.20 pg/ml, P>0.05).
Compared with Pixu group, There wasn't statistical significance between Zhuodu group and Pixu group(302.89±126.82pg/ml VS 208.72±85.21 pg/ml, P>0.05).
Conclusions:
1 The level of gastrin and motilin in blood plasma have variability in different type of syndrome of TCM of CAG .
2 The change of the level of gastrin and motilin in blood plasma may be the reason to induce the different clinical manifestation among different type of syndrome.
Part 3: Observated the clinical curative effect of chronic atrophic gastritis with intestinal metaplasia based on Zhuodu theory
Objective:This research aimed to observe clinical effect of treating chronic atrophic gastritis with intestinal metaplasia based on zhuodu doctrine.
Methods: 92 patients of CAG with intestinal metaplasia were collected from the Medical Department of Digestion of TCM Hospital of Hebei Province. They were randomly divided into treatment group and control group.Treatment group were given Hua Zhuo Jie Du decoction twice a day and one pouch in once for treatment, but control group were given Wei Fu Chun three times a day and four pills in once for treatment. One course of treatment was 12 weeks,two course of treatment in all.
Results:
1 The compairson of clinical therapeutic effect between two groups:A total of 52 cases of treatment group, 17 cases of clinical recovery, 21 cases of clinical markedly, 11 cases of effective, 3 cases of invalid, the total effective rate was 94.23%. A total of 40 cases of control group, 7 cases of clinical recovery, 10 cases of clinical markedly, 8 cases of effective, 15 cases of invalid, the total effective rate was 62.5%. The difference of clinical curative effect between two groups was significant (P<0.01).
2 The compairson of cardinal symptom score between two groups: After treating, the score of stomach pain, swelling of the liver is full, belching and debilitation decreased obviously in two groups.There was a significant difference bewteen before and after treating (treatment group and:1.32±0.51VS 4.82±1.25 P <0.01; control group:1.58±0.65 VS 4.69±1.17, P <0.01). After treatment, treatment group in the above-mentioned symptoms was significantly lower than the control group, there was a significant difference (1.32±0.51 VS 1.58±0.65, P<0.05).
3 The compairson of gastroscopic effect between two groups: Gastroscopic curative effect of treatment group was superior to control group (The total effective rate in treatment group were 86.96%, 92%, 64.58%, 71.42%, 65.63%,the total effective rate control group were 60%, 78.95%, 38.23%, 36.36%, 31.82%, P<0.05 or P<0.01). Treatment group and control group comparisons to improve the mucosal oedema was no significant difference(The total effective rate in treatment group were 87.5%, the total effective rate control group were71.88%, P>0.05)
4 The compairson of Gastic mucosa’pathological curative effect between two groups:The total effective rates of Treatment group in the improvement of gastric atrophy and IM, were 78.85%, 84.62%. The total effective rate control group were 52.5%, 55%. Gastic mucosa’pathological curative effect of treatment group was superior to control group(P<0.01).
5 The compairson of the teradication rate of Hp between two groups: Two groups’curative effect of resising Hp infection were 47.22% and 44.44%. Two groups’curative effect of resisting Hp infection had no significant difference (P>0.05) .
6 Detection of security indicators:There is no abnormal changes for Observation of blood, urine, conventional liver and kidney function and ECG changes before and after.
Conclusions:
1 Huazhuo Jiedu decoction can improve clinical symptoms in patients with CAG.
2 Huazhuo Jiedu decoction can recover the gastric mucosa and improve intestinal metaplasia.
3 Huazhuo Jiedu decoction can surely and partially resist Hp infection.
Part 4:The effect on multiplication and apoptosis of human gastric cancer cell with drug-containing serum of Huazhuo Jiedu decoction and separate decoction
Objective: We observed the effect of multiplication and apoptosis to BGC-823 with drug-containing serum of Huazhuo Jiedu decoction and separate decoction in the experiment. The aim of it was to investigate if the Huazhuo Jiedu decoction could prevent precancerosis of CAG by the mechanism of action of inhibiting the cell to multiply and provide experimental evidence for clinical application.
Methods:
1 The preparation of drug-containing serum: 20 healthy male SD rats were randomly divided into four groups: normal group, Huazhuo Jiedu decoction group, Huazhuo decoction group, Jiedu decoction group.The amount of medicinal herb given to rats in Huazhuo Jiedu decoction group, Huazhuo decoction group, Jiedu decoction group was 345.9g·kg~(-1)·d~(-1),208.4g·kg~(-1)·d~(-1),137.3g·kg~(-1)·d~(-1) weight respectively. Normal group were given 2ml isotonic Na chloride once a day by intragastric administration for 3 days. After anesthetizing by intraperitoneal injection hydral(350mg/kg), all rats were killed and draw blood by abdominal aorta. After standing, centrifugd for 10min, 3000rpm/min, deactivated by 56℃for 30min, finally, conserved in frigidaire -20℃for pre-emergency.
2 Administration and subgroup: we treated BGC-823 cell with blank pastilleserum, Huazhuo Jiedu drug-containing serum, Huazhuo decoction drug-containing serum, jiedu drug-containing serum. We departed them into four groups, Huazhuo Jiedu decoction group, Huazhuo decoction group, Jiedu decoction group and control group.
3 Detected the index: we deployed MTT, flow cytometry, cell immunohistochemistry to detect the growth inhibiting, cell cycle, apoptosis rate, the expression of Bcl-2 and Bax proteinum in BGC-823 cell with different drug-containing serum.
Results:
1 The experiment on inhibitation the multiplication of cell: Compared with control group, there was effect on inhibitation the multiplication of BGC-823 cell with Huazhuo Jiedu decoction, Huazhuo decoction and Jiedu decoction (P<0.05,P<0.01), especially, the effect of Huazhuo Jiedu decoction was evident, the rate of inhititation was 39.3%, 16.8%, 16.5% respectively. There was no different between Huazhuo decoction and Jiedu decoction in the effect of inhibitation.
2 cell cycle: compared with normal group, great changes had happened in the cell cycle of BGC-823 with Huazhuo Jiedu decoction. The number of cell in G0/G1 stage increased (P<0.01), the number of cell in S stage decreased(P<0.01),there was no changes in G2/M stage, most of cells was hold in G0/G1 stage. But there was no changes in the cell cycle of BGC-823 with Huazhuo decoction and Jiedu decoction (P>0.05).
3 Apotosis rate: the BGC-823 was treated with different Drug-containing serum, the bar chart of DNA emerged typical hypodiploid apoptotic peak.The result of FCM: the apotosis rate in Huazhuo Jiedu group prescription,Huazhuo decoction group and Jiedu decoction group was (16.85±0.63)%, (11.48±0.50)%, (12.38±0.60)% respectively.Compared with normal group (2.09±0.25)%, there was significant difference between them (P <0.01).There was significant difference between Huazhuo Jiedu decoction group, Huazhuo decoction group and Jiedu decoction group in apotosis rate (P <0.01). There was no difference, Huazhuo decoction group and Jiedu decoction group in apotosis rate (P>0.05).
4 Detected the expression of Bcl-2 and Bax proteinum by cell immunohistochemistry: the masculine rate of expression Bcl-2 proteinum in huazhuojiedu group prescription, Huazhuo decoction group and Jiedu decoction group decreased greatly and they were (29.73±4.34)%, (37.11±4.63)%, (41.63±6.47)% respectively. Compared with normal group (53.74±2.97)%, there was significant statistical difference (P<0.01). There was significant difference between Huazhuo Jiedu decoction group,Huazhuo decoction group and Jiedu decoction group in the masculine rate of expression Bcl-2 proteinum (P<0.01). But there was no difference between Huazhuo decoction group and Jiedu decoction group (P>0.05). The masculine rate of expression Bax proteinum in huazhuojiedu group prescription, Huazhuo decoction group and Jiedu decoction group was (58.11±4.19)%, (32.25±2.93)%, (34.84±2.66)% respectively. Compared with normal group (25.17±2.36), there was significant difference (P<0.01). There was significant difference between Huazhuo Jiedu decoction group, Huazhuo decoction group and Jiedu decoction group in the masculine rate of expression Bax proteinum (P<0.01). But There was no difference between Huazhuo decoction group and Jiedu decoction group (P>0.05).
5 Detected the expression of Bcl-2 and Bax proteinum with flow cytometry:Compared with normal group the expression of Bcl-2 in Huazhuo Jiedu group prescription,Huazhuo decoction group and Jiedu decoction group decreased (257.67±9.02 VS 330.22±7.13 P<0.01; 291.22±11.07 VS 330.22±7.13 P<0.01;276.20±9.10VS330.22±7.13 P<0.01).But the expression of Bax proteinum increased (330.14±8.19 VS 281.23±12.71 P<0.01; 303.84±6.60 VS 281.23±12.71P<0.05; 310.54±13.29 VS 281.23±12.71, P<0.01).There was significant difference between Huazhuo Jiedu decoction group, Huazhuo decoction group and Jiedu decoction group in the expression of Bcl-2 and Bax proteinum (P<0.01). There was no difference between Huazhuo decoction group and Jiedu decoction group in the expression of Bcl-2 and Bax proteinum(P>0.05).
Conclusions:
1 Huazhuo Jiedu decoction can inhibit BGC-823 cell multiplication, because it can interact cell cycle and induce apoptosis.
2 Huazhuo Jiedu decoction, Hua Zhuo decoction and Jie Du decoction induce apoptosis may be according to increase the expression of Bcl-2 proteinum and decrease the expression of Bax proteinum in BGC-823 cell.
3 Huazhuo decoction and Jiedu decoction can induce apoptosis, but it can not influence the cell cycle. The compatibility of Huazhuo Jiedu decoction can retard cell in G0/G1 stage, therefore it has remarkable effect on inhibiting the BGC-823 cell multiplication of gastric adenocarcinoma.
Conclusions:
1 Our study investigated the problem about the type of syndrome in TCM and indicated that Zhuodu Zheng is one common type of syndrome of CAG by the the way of cluster analysis.
2 The level of gastrin and motilin in blood plasma have variability in different type of syndrome of traditional chinese medicine of CAG. The change of the level of gastrin and motilin in blood plasma may be the reason to induce the different clinical manifestation among different type of syndrome.
3 Huazhuo Jiedu decoction can improve clinical symptoms and intestinal metaplasia , recove gastric mucosa in CAG patients.
4 The drug-containing serum of Huazhuo Jiedu decoction and separate decoction can inhibit BGC-823 cell to multiply and enhance to apoptosis. It is possible the one of mechanism of this prescription prevented gastric cancer and reversed precancerosis.
中医学将CAG病变归属于“胃脘痛”、“胃痞”、“痞满”、“嘈杂”等病证范畴。导师李佃贵教授认为,随着社会的发展,生活方式、饮食结构的改变,环境因素变化,包括大气污染等,现代人的精神社会压力加大,疾病模式会发生变化。在临床诊疗中观察到许多慢性疾病患者病情反复,缠绵难愈,常有颜面晦浊、暗滞,少泽,大便粘腻不爽,小便黄,舌质暗红,苔黄或黄腻,脉弦滑等脉证表现,李师在总结前人理论的基础上,结合多年的临证经验,提出“浊毒学说”,认为浊毒既是一种对人体脏腑经络及气血阴阳均能造成严重损害的致病因素,同时也是多种病因导致脏腑功能紊乱、气血运行失常,机体内产生的代谢产物不能及时正常排出,蕴积体内而化生的病理产物。其致病特点,(1)粘滞难解易阻遏气机;(2)入血入络易伤气阴;(3)气血失调易瘀易积。浊毒为患所造成的病证,属于浊毒证,是指以浊毒为病因使机体处于浊毒状态从而产生特有临床表现的一组或几组证候群。运用浊毒学说指导CAG治疗,初步取得了较为满意的临床疗效。本研究旨在进一步完善该学说在CAG的证候规律,探讨化浊解毒方药的作用机制。
目前,中医关于CAG的证候分型,行业学会及各家经验存在多种不同的观点,如有肝胃不和、脾胃湿热、湿浊中阻、胃络瘀阻、脾胃虚弱、胃阴不足6个证型分类;有肝胃不和、脾胃虚弱(含虚寒)、脾胃湿热、胃阴不足、胃络瘀阻、脾虚气滞等证型分类;还有的分为气阴两虚,虚火灼胃和脾胃气虚证型等等,繁杂不一,为临床和科研工作带来极大不便。
中医证候学研究是目前中医药研究工作的前沿领域,20年来,随着统计学、流行病学、计量学、模糊数学等诸多学科知识的不断渗透,被用于中医证候诊断标准量化研究的方法也日益增多。聚类分析是将样品个体或变量指标按其具有的特性进行分类的一种多元统计方法,分为样品聚类分析和变量聚类分析,其目的是根据样品或指标间相似程度的大小,将性质相近的归在同一类,而将性质相差比较大的归在不同的类,在中医证候研究中的合理应用能够极大地提高中医辨证的规范性和准确性。
本研究采用聚类分析的方法,分析CAG较大样本病例的临床表现,以期为临床提供较为合理、科学、规范的辨证分型,同时,通过应用本方法来探讨浊毒证的证候规律。
观察CAG浊毒证患者的胃泌素(Gas)、胃动素(MTL)、生长抑素(SS)水平变化,探讨CAG浊毒证证型与胃肠激素之间的相关关系,进一步明确胃肠激素的变化在CAG中医证型中是否有特异性,胃肠激素变化异常是否能导致不同证型临床征象,提高对本证型的认识。
CAG属癌前疾病,CAG伴IM,被认为是萎缩的典型标志以及胃癌的前兆,通过上述分析,发现浊毒内蕴是本病的主要证候特点,为此,创立了化浊解毒方,并观察本方治疗CAG的临床疗效。
通过观察化浊解毒方药及其拆方含药血清对体外培养的人胃癌BGC-823细胞增殖和凋亡的影响,从实验研究方面,进一步探讨化浊解毒方药在防治胃癌前病变中可能的作用机制。
第一部分慢性萎缩性胃炎证候学聚类研究
目的:采用变量聚类分析的方法,对CAG临床资料进行探索性的中医证候分类研究,旨在应用现代数理统计方法探索CAG较为规范的临床证候分型,验证浊毒证候的特点,为临床辨证提供客观依据。
方法:采集河北省中医院消化科门诊及住院CAG患者,所有患者依照西医诊断标准确诊为CAG,符合纳入、排除标准。记录371例CAG患者的症状、体征、舌象和脉象等临床资料,使用SAS软件对56个变量进行3-6类的聚类分析。
结果:确定CAG患者中医证候分为:浊毒内蕴、肝胃不和、胃络瘀阻、脾胃虚弱、胃阴不足5类,其解释比例为72.74%,并初步确定了各证候诊断的主症、次症。浊毒内蕴证诊断:主症:畏寒肢冷,胃脘隐痛,苔黄、厚、腻,脉细、滑;次症:胸闷,胁胀痛,口臭,脉沉、缓。肝胃不和证诊断:主症:胃脘胀满,嗳气,脉弦;次症:嘈杂,反酸,易怒,饮食减少,嗳腐吞酸。胃络瘀阻证诊断:主症:胃脘刺痛,拒按,面色暗滞,脉涩;次症:恶心,舌有瘀点、瘀斑,苔薄。脾胃虚弱证诊断:主症:胃脘痞满,气短,便溏,舌有齿痕;次症:面色萎黄,腹痛欲泻,乏力,舌淡,脉弱。胃阴不足证诊断:主症:胃脘胀痛,苔少或无,舌少津,舌有裂纹,大便干,脉数;次症:口干,失眠,脉迟。
小结:应用变量聚类分析,同时结合临床专家意见,能够帮助进行CAG中医证候的合理分类,并对提出的CAG新的证候类型—浊毒内蕴证进行了较为规范、科学的验证,为中医辨证论治CAG提供一定较为合理、科学的理论依据。
第二部分慢性萎缩性胃炎浊毒证与胃肠激素相关性研究
目的:本研究旨在通过探讨CAG浊毒证与胃肠激素分泌变化规律相关性研究,以揭示CAG浊毒证患者胃肠激素的分泌特点,提高对浊毒证的认识,为临床诊治提供客观指标方面的依据。
方法:采集河北省中医院2006年12月-2007年12月消化科门诊及住院的CAG患者50例,所有患者据符合西医诊断标准和中医辨证诊断标准,分为浊毒证组25例和脾虚证组25例,同时选取健康志愿者设立健康对照组25例。采用放射免疫法检测患者血浆胃泌素(Gas)、胃动素(MTL)、生长抑素(SS)的含量。
结果:
1血浆Gas水平
与健康组比较,CAG浊毒证组患者血浆Gas水平无明显变化,两组之间比较,差异无统计学意义(104.82±47.91 pg/ml VS 100.19±48.76 pg/ml, P>0.05)。
与健康组比较,CAG脾虚证组患者血浆Gas水平均下降明显,两组之间比较,差异有统计学意义(79.17±34.02 pg/ml VS 100.19±48.76 pg/ml, P<0.05)。
与CAG脾虚证组比较,CAG浊毒证组患者血浆Gas水平较高,两组之间比较,差异有统计学意义(104.82±47.91pg/ml VS 79.17±34.02 pg/ml, P<0.05)。
2血浆MTL水平
与健康组比较,CAG浊毒证组患者血浆MTL水平无明显变化,两组之间比较,差异无统计学意义(302.89±126.82 pg/ml VS 326.00±58.76 pg/ml, P>0.05)。
与健康组比较,CAG脾虚证组患者血浆MTL水平下降明显,两组之间比较,差异有统计学意义(208.72±85.21 pg/ml VS 326.00±58.76 pg/ml, P<0.05)。
与CAG脾虚证组比较,CAG浊毒证组患者血浆MTL水平较高,两组之间比较,差异有统计学意义(302.89±126.82pg/ml VS 208.72±85.21 pg/ml, P<0.05)。
3血浆SS水平
与健康组比较,CAG浊毒证组患者血浆SS水平无明显变化,两组之间比较,差异无统计学意义(11.81±6.34 pg/ml VS 10.10±7.20 pg/ml, P>0.05)。
与健康组比较,CAG脾虚证组患者血浆SS水平下降不明显,两组之间差异无统计学意义(10.95±6.87 pg/ml VS 10.10±7.20 pg/ml, P>0.05)。与CAG脾虚证组比较,两组血浆SS水平之间,差异无统计学意义(11.81±6.34pg/ml VS 10.95±6.87 pg/ml, P>0.05)。
小结:
1在CAG浊毒证患者中,血浆Gas、MTL的变化有证型特异性。
2血浆Gas、MTL的变化可能导致不同证型临床征象。
第三部分化浊解毒方治疗慢性萎缩性胃炎临床研究
目的:本文旨在通过观察化浊解毒方对CAG患者的症状积分、胃镜像、病理学、Hp等方面的影响,探讨该方治疗CAG的临床疗效。
方法:收集河北省中医院消化科门诊及住院的CAG患者共92例,随机分为治疗组和对照组,治疗组口服化浊解毒方治疗,1袋/次,2次/日,早、晚空腹温服。对照组口服中成药胃复春4片/次,3次/日。12周为1个疗程,连用2个疗程。
结果:
1两组临床疗效比较:治疗组52例中临床痊愈17例,显效21例,有效11例,无效3例,总有效率94.23%;对照组40例中临床痊愈7例,显效10例,有效8例,无效15例,总有效率62.5%。两组临床疗效比较,差异有统计学意义(P<0.01)。
2两组主要症状积分比较:两组治疗后胃痛、痞满、嗳气、纳差、乏力等症状积分明显减少,差异有统计学意义(治疗组:1.32±0.51 VS 4.82±1.25 P <0.01;对照组:1.58±0.65 VS 4.69±1.17, P <0.01);治疗后,治疗组症状积分明显低于对照组,与对照组比较,差异有统计学意义(1.32±0.51 VS 1.58±0.65, P<0.05)。
3两组胃镜疗效比较:治疗组胃镜结果显示在胃黏膜充血、糜烂、黏膜白象、黏膜粗糙、血管透见方面的疗效优于对照组,两组比较,差异有统计学意义(治疗组总有效率分别为86.96%、92%、64.58%、71.42%、65.63%,对照组总有效率分别为60%、78.95%、38.23%、36.36%、31.82%,P<0.05或P<0.01)。治疗组和对照组改善胃黏膜水肿的比较,差异无统计学意义(治疗组总有效率为87.5%、对照组总有效率71.88%,P>0.05)。
4两组病理疗效比较:治疗组在改善胃黏膜萎缩,肠上皮化生(IM)总有效率分别为78.85%、84.62%,对照组总有效率分别为52.5%、55%,治疗组明显优于对照组,两组比较,差异有统计学意义(P<0.01)。
5两组抗Hp感染疗效比较:治疗组和对照组抗Hp感染的根除率分别为47.22%和44.44%,两组的根除率比较,差异无统计学意义(P>0.05)。
6安全性指标检测:患者治疗前后血、尿、便常规及肝、肾功能和心电图的均无异常改变。
小结:
1化浊解毒方能够较好改善CAG患者的临床症状。
2化浊解毒方对胃黏膜的恢复、肠上皮化生的改善有较好疗效。
3化浊解毒方有一定的抗Hp感染作用。
第四部分化浊解毒方药及其拆方含药血清对人胃癌BGC-823细胞增殖和凋亡的影响
目的:本课题旨在通过观察化浊解毒方药及其拆方含药血清对人胃癌BGC-823细胞增殖和凋亡的影响,探讨该方药是否通过抑制细胞增殖作用机制,预防CAG癌前病变,为该方药临床应用提供实验依据。
方法:
1含药血清的制备:SD大鼠,雄性,随机分为4组:空白对照组、化浊解毒方组、化浊方组、解毒方组。实验组分别按345.9g·kg~(-1)·d~(-1)、208.4g·kg~(-1)·d~(-1)、137.3g·kg~(-1)·d~(-1)剂量灌胃,空白对照组2ml生理盐水灌胃,1次/日,共3次。末次给药后2h,常规分离血清保存。
2给药及分组:分别以各组的含药血清对胃腺癌BGC-823细胞进行干预,分为空白对照组、化浊解毒方组、化浊方组、解毒方组4组。
3检测指标:分别采用MTT、流式细胞术、免疫组化法检测不同含药血清对BGC-823细胞的生长抑制、细胞周期和凋亡率的影响及BGC-823细胞中Bcl-2、Bax蛋白的表达。
结果:
1细胞增殖抑制实验:与空白对照组比较,化浊解毒方、化浊方、解毒方,均对BGC-823细胞有抑制作用(P<0.05或P<0.01),抑制率分别为39.3%、16.5%、16.8%。尤以化浊解毒方效果显著,其抑制作用强于化浊方和解毒方(P<0.01),而化浊方组与解毒方组之间比较,差异无统计学意义(P>0.05)。
2 FCM对BGC-823细胞的细胞周期检测结果:与空白对照组比较,经化浊解毒方处理的BGC-823细胞的细胞周期发生明显变化,G0/G1期细胞明显增多(P<0.01),S期细胞比率显著下降(P<0.01),G2/M期无明显变化(P>0.05),多数细胞阻滞在G0/G1期。而化浊方、解毒方对BGC-823细胞的细胞周期无明显影响(P>0.05)。
3 FCM对BGC-823细胞凋亡率的检测结果
BGC-823细胞经不同含药血清处理48h后,DNA直方图上出现典型的亚二倍体凋亡峰。FCM结果显示:化浊解毒方组、化浊方组、解毒方组凋亡率分别为(16.85±0.63)%、(11.48±0.50)%,(12.38±0.60)%,与空白对照组(2.09±0.25)%比较,差异均有统计学意义(P<0.01);与化浊解毒方比较,化浊方组、解毒方组凋亡率有统计学意义(P<0.01);化浊方组与解毒方组比较,差异无统计学意义(P>0.05)。
4免疫组化检测Bcl-2、Bax蛋白表达
BGC-823细胞经化浊解毒方、化浊方、解毒方含药血清干预48h后,Bcl-2蛋白阳性表达率均明显降低,分别为(29.73±4.34)%、(41.63±6.47)%、(37.11±4.63)%,与空白对照组(53.74±2.97)%比较,差异均具有统计学意义(P<0.01)。化浊方组、解毒方组与化浊解毒方组比较,差异有统计学意义(P<0.01),而化浊方与解毒方两组比较,差异无统计学意义(P>0.05)。
Bax蛋白阳性表达率均显著升高,化浊解毒方组、化浊方组、解毒方组阳性表达率分别为(58.11±4.19)%、(32.25±2.93)%、(34.84±2.66)%,与空白对照组(25.17±2.36)%比较,差异均有统计学意义(P<0.01)。化浊方组、解毒方组与化浊解毒方比较,差异有统计学意义(P<0.01),而解毒方与化浊方两组比较,差异无统计学意义(P>0.05)。
5流式细胞术检测Bcl-2、Bax蛋白表达
流式细胞仪检测结果显示,与空白对照组比较,化浊解毒方、化浊方、解毒方作用于胃癌BGC-823细胞48h后,Bcl-2蛋白表达均明显降低,具有统计学意义(257.67±9.02 VS 330.22±7.13;291.22±11.07 VS 330.22±7.13;276.20±9.10 VS 330.22±7.13 ,P均<0.01);细胞内Bax蛋白表达水平均增高,具有统计学意义(330.14±8.19 VS 281.23±12.71,P<0.01;303.84±6.60 VS 281.23±12.71, P<0.05;310.54±13.29 VS 281.23±12.71,P<0.01)。
Bcl-2蛋白和Bax蛋白表达水平,与化浊解毒方组比较,解毒方组、化浊方组差异均有统计学意义(分别为P<0.01,P<0.05);解毒方组与化浊方组比较,差异无统计学意义(P>0.05)。
小结:
1化浊解毒方可抑制人胃腺癌BGC-823细胞增殖,其作用机制可能与其干扰细胞周期,诱导细胞凋亡有关。
2化浊解毒方及其拆方发挥诱导凋亡作用的机制可能是通过上调促凋亡蛋白Bax的表达,下调凋亡抑制蛋白Bcl-2的表达来实现的。
3化浊方、解毒方均能诱导细胞凋亡,而对细胞周期无影响。经两者配伍后的化浊解毒方不仅能诱导细胞凋亡,而且能将细胞阻滞于G0/G1期,因此其对胃腺癌BGC-823细胞抑制增殖作用明显增强。
结论:
1应用变量聚类分析,能够帮助进行CAG中医证候的合理分类,并探讨CAG浊毒证证候特点,为中医辨证论治CAG提供一定较为合理、科学的理论依据。
2在CAG浊毒证患者中,血清Gas、MTL的变化有证型特异性。血浆Gas、MTL的变化可能导致不同证型临床征象。
3化浊解毒方药能够较好的改善CAG患者的临床症状,对胃黏膜的恢复、肠上皮化生的改善亦有较好疗效,并且有一定的抗Hp感染作用。
4化浊解毒方及其拆方含药血清对人胃癌BGC-823细胞增殖产生抑制作用,促进BGC-823细胞的凋亡,可能是该类方药预防胃癌及逆转癌前病变作用机制之一。
Chronic atrophic gastritis(CAG) is a common disease of digestive system. Its pathological changes was caused by inflammation, such as the destruction, reduce, shrink or even disappear of gastric glands, the loss of surface epithelial cell secretion capacity and mucosal thickening of the muscle. The last century 40's, Schindle first proposed the concept of CAG. WHO would be the CAG as a precancerous lesion of gastric cancer in 1978, CAG associated with intestinal metaplasia and dysplasia are precancerous lesions of gastric cancer. The possibility of cancer is larger. CAG and its precancerous lesions has become the focus of the study. Early detection, prevention and treatment of precancerous diseases and precancerous lesions, become a effective way of lower incidence and mortality of gastric cancer.The application of traditional Chinese medicine(TCM) in the treatment of chronic atrophic gastritis has a distinct advantage, the improvement of patient symptoms and to correct the effect of disease and so on, it is affirmative and significant.
CAG disease would be attributed to "Epigastralgia, gaster-mass, consumptive disease" syndrome in TCM. Professor Diangui Li thinks that modern people’s pressure of spirit and society become larger and disease patterns will changes with the development of society, lifestyle and diet changes. We observed many patients with chronic diseases that their conditions were repeated and refractory lingering in the clinical treatment.They had several clinical manifestations,such as dark cloud complexion, dark stagnation and less burnish, sticking and greasy stool, yellow urine, dark red body of the tongue, surname or greasy coated tongue, slippery pulse and so on. Professor Diangui Li introduced Zhuodu theory in the base of summarizing predecessor’s theory combined with years of clinical experience .He think Zhuodu is one of pathopoiesis factors which can cause serious harm on the human entrails and meridian and the QI-blood of yin and yang. Meanwhile, it’s the pathological products came from metabolic products which accumulated in the body when it’s entrails functional disorders and QI-blood circulation is not normal.Three pathogenic characteristics of Zhuodu: (1)Zhuodu is hard to dissolve and easy inducing disorder of vital energy.(2) Zhuodu is easy entering blood and collaterals and inducing disorder of vital energy.(3) Zhuodu is easy inducing incoordination between vital energy and blood and forming blood stasis. The symptoms caused by Zhuodu belong to Zhuodu Zheng. It refers to a group or several groups of syndromes group which have specific clinical manifestations when the body is in the state of Zhuodu caused by Zhuodu.We have obtained a relatively satisfactory clinical efficacy applying Zhuodu theory in the treatment of CAG. The study aims at consummating further the symptoms law of the theory in CAG and exploring the mechanism of Huazhuojiedu prescription.
At present, it is discordant that the viewpoint of many institute and medical scientist about the typing of CAG in TCM. Some Chinese medical scientist consider that the typing of CAG is GanWeiBuHe, PiWeiShiRe, ShiZhuoZhongZu, WeiLuoYuZu, PiWei XuRuo, WeiYingBuZu. But other Chinese medical scientist considered that the typing of CAG is GanWeiBuHe, PiWeiXuRuo, PiWeiShiRe, WeiYingBuZu, WeiLuoYuZu, PiXuQiZhi. At the same time, some Chinese medical scientist consider that the typing of CAG is QiYing LiangXu, XuHuoZuo Wei, PiWeiQiXu. The discrepancy about the typing of CAG in TCM increase difficulty in evolving clinical work and scientific research.
The study about the symptom of TCM is the frontline of the research on TCM. Over 20 years, the investigative methods of quantizating applicated in studying on diagnostic criteria of Chinese medical symptom are increasing along with the permeating of the knowledge of statistics, epidemiology, metrology, vague mathematics and so on. Cluster analysis is one kind of multivariant statistical method whice can sort the sample or variables index to sample cluster analysis or variables cluster analysis according to theirs characteristics. Cluster analysis aims to classify those samples or variables index whice have similar character into one sort according to the similar degree among the samples or variables indexs. Reasonable application of cluster analysis in study on Chinese medical symptom can enormously raise specification and accuracy rating of differentiation of symptoms and signs in TCM.
In this study, we have adopted the way of cluster analysis to analysis of large sample of cases of clinical manifestations and aim to provide reasonable scientific and normative differentiation of symptoms and signs for classification of syndrome for clinical, to investigate the regularity of symptoms and signs of Zhuodu Zheng.
We tried to explore correlativity of the Zhuodu Zheng with the gut hormones by observing the change of the level of Gas, MTL and SS in patients of CAG and definite if the change of the level of gut hormones have variability in different type of syndrome of TCM, and if the abnormal content of gut hormones can lead different type of syndrome. The study can elevate our recognition about the Zhuodu Zheng of CAG.
CAG is a kind of premalignant disease. CAG combining IM was known as atrophic typical indicate and gastric carcinomatous premonition. Through above-mentioned analysis, it was discovered that Zhuodu NeiYun was the principal characteristic of symptom of CAG, so we formulated HuaZhuoJieDu decoction and observed the curative effect of Huazhuo Jiedu decoction on treating CAG combining IM.
At experimental point of view, we explored the possible mechanism of Huazhuo Jiedu to prevent and cure gastric carcinomatous precancerosis by observing the effect of Huazhuo Jiedu and their separate Huazhuo Jiedu decoction containing serum on proliferation and apoptosis of cultured human gastric cancer BGC-823 cell in vitro.
Part 1: Study on Symptoms of Chronic atrophic gastritis in Traditional Chinese medicine by the way of Cluster analysis
Objective:The study on the clinical data of CAG probed the regularity of different type of syndrome of TCM of CAG by the way of Cluster analysis. The study aims at exploring normative typing of syndrome of TCM of CAG and providing objective evidence for clinical differentiation of symptoms and signs by the way of modern mathematical statistics.
Methods: The 371 patients visiting the clinic service or being in hospital at the Medical Department of Digestion of TCM Hospital of Hebei Province were diagnosed CAG according to the diagnostic criteria in modern medicine. Those patients are accordance with the criteria of internalizing and removing. The sysptoms,physical sign, tongues demonstration and pulse tracings of the 371 patients of with CAG were collected and recorded. We did Cluster analysis by SAS software for 56 variables through sorting 3-6 types.
Results: The syndromes of these CAG Patients could be divided into 5 types: ZhuoDuNeiYun, GanWeiBuHe, WeiLuoYuZu, PiWeiXuRuo, WeiYing BuZu. The proportion explained was 72.74%. The principal and minor symptom of each type of syndromes of these CAG initially definited. The diagnostic criteria of ZhuoDuNeiYunZheng: the principal symptom and sign: chilly and cold limbs, stomachache, yellow thick and greasy fur,samll and smooth pulse; the minor symptom and sign: full sensation in the chest, distending pain over hypochondrium, halitosis, sunken pulse, even and soft pulse. The diagnostic criteria of GanWeiBuHeZheng: the principal symptom and sign: distention of stomach, eructation, wiry pulses; the minor symptom and sign: gastric upset, sour regurgitation, ill-temper, anorexia, eructation with foul odour and acidr regurgitation. The diagnostic criteria of WeiLuoYuZuZheng: the principal symptom and sign: prickle of stomach and tenderness, dimmish blackish complexion ,unsmooth pulses; the minor symptom and sign: nausea, tongue with ecchymosis, thin fur;The diagnostic criteria of PiWeiXu RuoZheng: the principal symptom and sign:felling of fulless and oppression, shortness of breath, loose stool, tongue with teeth marks on its margin; the minor symptom and sign:s,allow complexion, abdominal pain, acratia, pale tongue, weak pulse. The diagnostic criteria of WeiYing BuZuZheng: the principal symptom and sign: distending pain of stomach, tongue without fur, fissuared tongue, constipation, ripid pulses; the minor symptom and sign: dry mouth, sleepessness, slow pulse.
Conclusions: The way of variable cluster analysis combined with the opinions of clinical expert could help us do reasonable syndrome differentiation for CAG patients. Meanwhile, ZhuoDuNeiYunZheng was inspected and verified rationally and scientifically as one new type of syndrome of CAG by the study. The study provides certain reasonable and scientific theoretical foundation for CAG on selection of treatment based on the differential diagnosis.
Part 2: Study on dependablity of Zhuo Du Zheng of Chronic Atrophic Gastritis with Gut Hormone
Objective: The study aims to reveal the characteristic of gut hormone secretion of the patient of CAG Zhuo Du Zheng and to provid objective evidence on indicatrix by investigating the dependablity of Zhuo du zheng with the changing of gut hormone.
Methods: 50 patients who visited the Medical Department of Digestion of Traditional Chinese Medicine Hospital of Hebei Province between December, 2006 and December, 2007 were diagnosed CAG according to diagnostic criteria in modern medicine. Those patients who lived up to the criteria to internalize were divided into Zhuo Du group and Pi Xu group according to diagnostic criteria in Traditional Chinese Medicine. Healthy normal group also were composed of 25 healthy volunteers. The number of people in three groups all was 25.The level of gastrin, motilin and somatostatin in blood plasma were detected by radio-immunifaction.
Results:
1 The level of Gas in blood plasma
Compared with normal group, the level of gastrin in blood plasma of Zhuodu group didn't have marked change, there wasn't statistical significance between two groups(104.82±47.91 pg/ml VS 100.19±48.76 pg/ml, P>0.05).
Compared with normal group, the level of gastrin in blood plasma of Pixu group remarkably decreased. There was statistical significance between two groups(79.17±34.02 pg/ml VS 100.19±48.76 pg/ml, P<0.05).
Compared with Pi Xu group, the level of gastrin in blood plasma of Zhuodu group was higher. There was statistical significance between two groups(104.82±47.91pg/ml VS 79.17±34.02 pg/ml, P<0.05).
2 The level of MTL in blood plasma
Compared with normal group, the level of motilin in blood plasma of Zhuodu group didn't have marked change, there wasn’t statistical significance between two groups(302.89±126.82 pg/ml VS 326.00±58.76 pg/ml, P>0.05).
Compared with normal group, the level of motilin in blood plasma of Pixu group remarkably decreased. There was statistical significance between two groups(208.72±85.21 pg/ml VS 326.00±58.76 pg/ml, P<0.05).
Compared with Pixu group, the level of motilin in blood plasma of Zhuodu group was higher. There was statistical significance between two groups(302.89±126.82pg/ml VS 208.72±85.21 pg/ml, P<0.05).
3 The level of SS in blood plasma
Compared with normal group, the level of somatostatin in blood plasma of Zhuodu group didn't have marked change, there wasn't statistical significance between two groups(11.81±6.34 pg/ml VS 10.10±7.20 pg/ml, P>0.05).
Compared with normal group, the level of somatostatin in blood plasma of Pixu group didn't decreased. There wasn't statistical significance between two groups(10.95±6.87 pg/ml VS 10.10±7.20 pg/ml, P>0.05).
Compared with Pixu group, There wasn't statistical significance between Zhuodu group and Pixu group(302.89±126.82pg/ml VS 208.72±85.21 pg/ml, P>0.05).
Conclusions:
1 The level of gastrin and motilin in blood plasma have variability in different type of syndrome of TCM of CAG .
2 The change of the level of gastrin and motilin in blood plasma may be the reason to induce the different clinical manifestation among different type of syndrome.
Part 3: Observated the clinical curative effect of chronic atrophic gastritis with intestinal metaplasia based on Zhuodu theory
Objective:This research aimed to observe clinical effect of treating chronic atrophic gastritis with intestinal metaplasia based on zhuodu doctrine.
Methods: 92 patients of CAG with intestinal metaplasia were collected from the Medical Department of Digestion of TCM Hospital of Hebei Province. They were randomly divided into treatment group and control group.Treatment group were given Hua Zhuo Jie Du decoction twice a day and one pouch in once for treatment, but control group were given Wei Fu Chun three times a day and four pills in once for treatment. One course of treatment was 12 weeks,two course of treatment in all.
Results:
1 The compairson of clinical therapeutic effect between two groups:A total of 52 cases of treatment group, 17 cases of clinical recovery, 21 cases of clinical markedly, 11 cases of effective, 3 cases of invalid, the total effective rate was 94.23%. A total of 40 cases of control group, 7 cases of clinical recovery, 10 cases of clinical markedly, 8 cases of effective, 15 cases of invalid, the total effective rate was 62.5%. The difference of clinical curative effect between two groups was significant (P<0.01).
2 The compairson of cardinal symptom score between two groups: After treating, the score of stomach pain, swelling of the liver is full, belching and debilitation decreased obviously in two groups.There was a significant difference bewteen before and after treating (treatment group and:1.32±0.51VS 4.82±1.25 P <0.01; control group:1.58±0.65 VS 4.69±1.17, P <0.01). After treatment, treatment group in the above-mentioned symptoms was significantly lower than the control group, there was a significant difference (1.32±0.51 VS 1.58±0.65, P<0.05).
3 The compairson of gastroscopic effect between two groups: Gastroscopic curative effect of treatment group was superior to control group (The total effective rate in treatment group were 86.96%, 92%, 64.58%, 71.42%, 65.63%,the total effective rate control group were 60%, 78.95%, 38.23%, 36.36%, 31.82%, P<0.05 or P<0.01). Treatment group and control group comparisons to improve the mucosal oedema was no significant difference(The total effective rate in treatment group were 87.5%, the total effective rate control group were71.88%, P>0.05)
4 The compairson of Gastic mucosa’pathological curative effect between two groups:The total effective rates of Treatment group in the improvement of gastric atrophy and IM, were 78.85%, 84.62%. The total effective rate control group were 52.5%, 55%. Gastic mucosa’pathological curative effect of treatment group was superior to control group(P<0.01).
5 The compairson of the teradication rate of Hp between two groups: Two groups’curative effect of resising Hp infection were 47.22% and 44.44%. Two groups’curative effect of resisting Hp infection had no significant difference (P>0.05) .
6 Detection of security indicators:There is no abnormal changes for Observation of blood, urine, conventional liver and kidney function and ECG changes before and after.
Conclusions:
1 Huazhuo Jiedu decoction can improve clinical symptoms in patients with CAG.
2 Huazhuo Jiedu decoction can recover the gastric mucosa and improve intestinal metaplasia.
3 Huazhuo Jiedu decoction can surely and partially resist Hp infection.
Part 4:The effect on multiplication and apoptosis of human gastric cancer cell with drug-containing serum of Huazhuo Jiedu decoction and separate decoction
Objective: We observed the effect of multiplication and apoptosis to BGC-823 with drug-containing serum of Huazhuo Jiedu decoction and separate decoction in the experiment. The aim of it was to investigate if the Huazhuo Jiedu decoction could prevent precancerosis of CAG by the mechanism of action of inhibiting the cell to multiply and provide experimental evidence for clinical application.
Methods:
1 The preparation of drug-containing serum: 20 healthy male SD rats were randomly divided into four groups: normal group, Huazhuo Jiedu decoction group, Huazhuo decoction group, Jiedu decoction group.The amount of medicinal herb given to rats in Huazhuo Jiedu decoction group, Huazhuo decoction group, Jiedu decoction group was 345.9g·kg~(-1)·d~(-1),208.4g·kg~(-1)·d~(-1),137.3g·kg~(-1)·d~(-1) weight respectively. Normal group were given 2ml isotonic Na chloride once a day by intragastric administration for 3 days. After anesthetizing by intraperitoneal injection hydral(350mg/kg), all rats were killed and draw blood by abdominal aorta. After standing, centrifugd for 10min, 3000rpm/min, deactivated by 56℃for 30min, finally, conserved in frigidaire -20℃for pre-emergency.
2 Administration and subgroup: we treated BGC-823 cell with blank pastilleserum, Huazhuo Jiedu drug-containing serum, Huazhuo decoction drug-containing serum, jiedu drug-containing serum. We departed them into four groups, Huazhuo Jiedu decoction group, Huazhuo decoction group, Jiedu decoction group and control group.
3 Detected the index: we deployed MTT, flow cytometry, cell immunohistochemistry to detect the growth inhibiting, cell cycle, apoptosis rate, the expression of Bcl-2 and Bax proteinum in BGC-823 cell with different drug-containing serum.
Results:
1 The experiment on inhibitation the multiplication of cell: Compared with control group, there was effect on inhibitation the multiplication of BGC-823 cell with Huazhuo Jiedu decoction, Huazhuo decoction and Jiedu decoction (P<0.05,P<0.01), especially, the effect of Huazhuo Jiedu decoction was evident, the rate of inhititation was 39.3%, 16.8%, 16.5% respectively. There was no different between Huazhuo decoction and Jiedu decoction in the effect of inhibitation.
2 cell cycle: compared with normal group, great changes had happened in the cell cycle of BGC-823 with Huazhuo Jiedu decoction. The number of cell in G0/G1 stage increased (P<0.01), the number of cell in S stage decreased(P<0.01),there was no changes in G2/M stage, most of cells was hold in G0/G1 stage. But there was no changes in the cell cycle of BGC-823 with Huazhuo decoction and Jiedu decoction (P>0.05).
3 Apotosis rate: the BGC-823 was treated with different Drug-containing serum, the bar chart of DNA emerged typical hypodiploid apoptotic peak.The result of FCM: the apotosis rate in Huazhuo Jiedu group prescription,Huazhuo decoction group and Jiedu decoction group was (16.85±0.63)%, (11.48±0.50)%, (12.38±0.60)% respectively.Compared with normal group (2.09±0.25)%, there was significant difference between them (P <0.01).There was significant difference between Huazhuo Jiedu decoction group, Huazhuo decoction group and Jiedu decoction group in apotosis rate (P <0.01). There was no difference, Huazhuo decoction group and Jiedu decoction group in apotosis rate (P>0.05).
4 Detected the expression of Bcl-2 and Bax proteinum by cell immunohistochemistry: the masculine rate of expression Bcl-2 proteinum in huazhuojiedu group prescription, Huazhuo decoction group and Jiedu decoction group decreased greatly and they were (29.73±4.34)%, (37.11±4.63)%, (41.63±6.47)% respectively. Compared with normal group (53.74±2.97)%, there was significant statistical difference (P<0.01). There was significant difference between Huazhuo Jiedu decoction group,Huazhuo decoction group and Jiedu decoction group in the masculine rate of expression Bcl-2 proteinum (P<0.01). But there was no difference between Huazhuo decoction group and Jiedu decoction group (P>0.05). The masculine rate of expression Bax proteinum in huazhuojiedu group prescription, Huazhuo decoction group and Jiedu decoction group was (58.11±4.19)%, (32.25±2.93)%, (34.84±2.66)% respectively. Compared with normal group (25.17±2.36), there was significant difference (P<0.01). There was significant difference between Huazhuo Jiedu decoction group, Huazhuo decoction group and Jiedu decoction group in the masculine rate of expression Bax proteinum (P<0.01). But There was no difference between Huazhuo decoction group and Jiedu decoction group (P>0.05).
5 Detected the expression of Bcl-2 and Bax proteinum with flow cytometry:Compared with normal group the expression of Bcl-2 in Huazhuo Jiedu group prescription,Huazhuo decoction group and Jiedu decoction group decreased (257.67±9.02 VS 330.22±7.13 P<0.01; 291.22±11.07 VS 330.22±7.13 P<0.01;276.20±9.10VS330.22±7.13 P<0.01).But the expression of Bax proteinum increased (330.14±8.19 VS 281.23±12.71 P<0.01; 303.84±6.60 VS 281.23±12.71P<0.05; 310.54±13.29 VS 281.23±12.71, P<0.01).There was significant difference between Huazhuo Jiedu decoction group, Huazhuo decoction group and Jiedu decoction group in the expression of Bcl-2 and Bax proteinum (P<0.01). There was no difference between Huazhuo decoction group and Jiedu decoction group in the expression of Bcl-2 and Bax proteinum(P>0.05).
Conclusions:
1 Huazhuo Jiedu decoction can inhibit BGC-823 cell multiplication, because it can interact cell cycle and induce apoptosis.
2 Huazhuo Jiedu decoction, Hua Zhuo decoction and Jie Du decoction induce apoptosis may be according to increase the expression of Bcl-2 proteinum and decrease the expression of Bax proteinum in BGC-823 cell.
3 Huazhuo decoction and Jiedu decoction can induce apoptosis, but it can not influence the cell cycle. The compatibility of Huazhuo Jiedu decoction can retard cell in G0/G1 stage, therefore it has remarkable effect on inhibiting the BGC-823 cell multiplication of gastric adenocarcinoma.
Conclusions:
1 Our study investigated the problem about the type of syndrome in TCM and indicated that Zhuodu Zheng is one common type of syndrome of CAG by the the way of cluster analysis.
2 The level of gastrin and motilin in blood plasma have variability in different type of syndrome of traditional chinese medicine of CAG. The change of the level of gastrin and motilin in blood plasma may be the reason to induce the different clinical manifestation among different type of syndrome.
3 Huazhuo Jiedu decoction can improve clinical symptoms and intestinal metaplasia , recove gastric mucosa in CAG patients.
4 The drug-containing serum of Huazhuo Jiedu decoction and separate decoction can inhibit BGC-823 cell to multiply and enhance to apoptosis. It is possible the one of mechanism of this prescription prevented gastric cancer and reversed precancerosis.
引文
1 Correa P.A human model of gastric carcinogenesis.Cancer Res,1988, 48: 3554-3560
2王建华,王晓贞,王顺道.中医证候学研究的思路和方法.北京中医药大学学报, 1999, 4(22): 13-15
3白云静,申洪波,孟庆刚.中医证候复杂性特征及证候研究思路探析.中国中医药信息杂志, 2004, 9(11): 754-756
4李梢.从维度与阶度探讨中医证候的特征及标准化方法.北京中医药大学学报, 2003, 3(26): 1-4
5中华医学会消化病学分会.全国慢性胃炎研讨会共识意见.胃肠病学, 2000, 5(2): 77-79
6中国中西医结合学会消化系统疾病专业委员会.慢性胃炎的中西医结合诊治方案(草案).中国中西医结合杂志, 2005, 25(2): 172-175
7郑筱萸.中药新药临床研究指导原则(试行).北京:中国医药科技出版社, 2002: 124-129
8李乾构,周学文,单兆伟.中华中医药学会脾胃病分会·中医消化病诊疗指南,北京:中国中医药出版社, 2006, 21
9姚乃礼,朱建贵,高荣林.中医证候鉴别诊断学.北京:人民卫生出版社, 2006:2
10国家技术监督局.中医临床诊疗术语·证候部分,北京:中国标准出版社,1997年,第1版: 23
11朱文峰.中医诊断学.北京:中国中医药出版社,1997: 340
12蔡江,李佃贵,裴林.从“浊”“毒”论治慢性萎缩性胃炎.中国中西医结合消化杂志, 2002, 10(1): 41
13李佃贵,李海滨,裴林,等.慢性萎缩性胃炎从浊毒论治.四川中医,2004,22(1):17-18
14胡立胜,周强.中医临床研究设计与SAS编程统计分析.北京:学苑出版社, 2004: 68-79
15董建华,田德禄,麻仲学,等.虚痞中药治疗观察.中国医药学报, 1989, 4: 412
16邢士杰,鞠洪捷.萎缩性胃炎60例辨证治疗和病理观察.中医药信息, 2000, 17(3): 29
17高富贵.慢性萎缩性胃炎中医辨证治疗108例.医学理论与实践, 2004, 17(8): 909
18陈良金.慢性萎缩性胃炎辨证分型与证候特点探析.时珍国医国药, 2005, 16(11): 1149.
19柯莹玲,单兆伟. 542例慢性萎缩性胃炎患者中医辨证分型与病因分析.辽宁中医杂志, 2006, 32(2): 161
20谢晶日,刘磊,李贺薇,等.慢性萎缩性胃炎的中医药研究概况时珍国医国药, 2008, 9(18): 2157-2158
21孙振球,徐勇勇.医学统计学.北京:人民卫生出版社, 2002, 1: 399
1高一心,孙涛. 237例老年人胃癌癌前病变随访分析.肿瘤防治杂志. 2001, 8(2): 118-119
2张学庸,张忠兵,陈希陶,等.萎缩性胃炎胃窦G细胞、组织胃泌素、胃液和血清胃泌素关系初步观察.中华消化杂志, 1984, 4(6): 6-7
3邱泽安,吴晓黎,孔德明,等.胃脘痛脾胃虚弱、脾胃湿热证与4种胃肠激素的变化及意义.亚太传统医药, 2007, 3(8): 28-31
4马艳君,黄岑汉.慢性胃炎中医辨证分型与血清胃泌素和胃动素表达相关性研究.现代中西医结合杂志, 2007, 16(33):4914-4916
5张万岱,智发朝,宋于刚.脾虚证患者血浆、胃液及胃窦十二指肠粘膜胃泌素含量的研究.新消化病学杂志, 1993, 1(特1):14-15
6中华医学会消化病学分会.全国慢性胃炎研讨会共识意见.胃肠病学,2000,5(2):77-79
7中国中西医结合学会消化系统疾病专业委员会.慢性胃炎的中西医结合诊治方案(草案).中国中西医结合杂志, 2005, 25(2): 172-175
8郑筱萸.中药新药临床研究指导原则(试行).北京:中国医药科技出版社, 2002: 124-129
9李乾构,周学文,单兆伟.中医消化病诊疗指南.北京:中国中医药出版社, 2006: 21
10蔡江,李佃贵,裴林.从“浊”“毒”论治慢性萎缩性胃炎.中国中西医结合消化杂志, 2002, 10(1): 41
11李佃贵,李海滨,裴林,等.慢性萎缩性胃炎从浊毒论治.四川中医,2004,22(1):17-18
12姚乃礼,朱建贵,高荣林.中医证候鉴别诊断学.北京:人民卫生出版社, 2006年,第2版: 316
13国家技术监督局.中医临床诊疗术语·证候部分,北京:中国标准出版社,1997年,第1版: 23
14孙凤蓬.胃泌素及其相关胃肠激素的研究进展.国外医学·生理、病理科学与临床分册, 2000, 20(3): 229
15陈智颖,徐鸰鸽,张恩民.慢性多灶萎缩性胃炎患者胃酸分泌与幽门螺杆菌感染及血清胃泌素的关系.临床内科杂志, 2008, 25(8): 523-526
16姚永莉,徐波,宋于刚,等.胃肠道功能紊乱与胃动素关系的实验研究.第一军医大学学报, 2001, 21(8): 602-603
17李红涛,吴开春,李彩宁,等.血清胃泌素对老年人慢性萎缩性胃炎的诊断.中华老年医学杂志. 2004, 23(4): 238
18田德禄.中医内科学.北京:人民卫生出版社, 2003, 177
19 Poitras P, Dumont A, Cuber JC, Boivin M and Trudel L. Cholinergicregulation of motilin release from isolated canine intestinal cells. Regulatory Peptides, 1992, 40: 30
20 Ryouichi T, Shigeru F, Katsuhisa T and Masahiro F. Studies on gastrointestinal hormone and jejunal interdigestive migrating motor complex in patients with or without early dumping syndrome after total gastrectomy with Roux-en-Y reconstruction for early gastric cancer. The American Journal of Surgery, 2003, 185, 354-59
21 K.Milenov and A.Shahbazian.Cholinergic pathways in the effect of motilin on the canine ileum and gallbladder motility:in vivo and in vitro experiments, Comparative Biochemistry and Physiology Part A: Physiology, 1995, 112: 403-410
22张锦坤,肖澎荣,吴紫霞,等.胃运动功能的研究.中华消化杂志, 1984, 4(4): 233
23陈方元.胃肠激素与胃肠运动.国外医学·消化系统疾病分册, 1992, 12: 2-6
24许昌泰,王奕,潘伯荣.萎缩性胃炎患者血清胃液脑肠肽的研究.新消化病学杂志, 1997, 5(11): 713
25高希言,任珊,赵欣纪.穴位贴敷对慢性萎缩性胃炎大鼠胃肠激素影响的实验研究.针刺研究, 2006, 31(2): 107-109
26孙凤蓬,宋于刚,覃汉荣.胃溃疡大鼠胃泌素、生长抑素和G、D细胞的变化.世界华人消化杂志. 2004, 12: 363-366
27李秋娟,仲来福,叶建新,等.大鼠实验性慢性萎缩性胃炎与胃黏膜生长抑素、胃泌素关系的研究.大连医科大学学报, 1999, 21: 89-91
1李乾构,周学文,单兆伟.中华中医药学会脾胃病分会·中医消化病诊疗指南.北京:中国中医药出版社, 2006:21
2 Correa P.A human model of gastric carcinogenesis. Cancer Res, 1988, 48: 3554-3560
3 Tatem atsu M, Tsukamoto T, Inada K. Stem cells and gastric cancer role of gastric and intestinal mixed intestinal metaplasia. Cancer Sci, 2003, 9(4):135-141
4中华医学会消化病学分会.全国慢性胃炎研讨会共识意见.胃肠病学,2000, 5(2): 77-79
5蔡江,李佃贵,裴林.从“浊”“毒”论治慢性萎缩性胃炎.中国中西医结合消化杂志.2002,10(1): 41
6郑筱萸.中药新药临床研究指导原则(试行).北京:中国医药科技出版社, 2002: 124-129
7中华医学会消化内镜学分会2003年《慢性胃炎的内镜分型分级标准及治疗的试行意见》.中华消化内镜杂志, 2004, 21(2)::77-78
8劳绍贤.胃癌癌前病变的基础与临床.广州:广东人民出版社, 2002:193
9中华医学会消化病学分会.幽门螺杆菌共识意见(2003·安徽桐城).胃肠病学, 2004, 9 (1):46-47
10 Mukaisho K, Miwa K, Kumagai H, et al. Gastric carcinogenesis by duodenal reflux through gut regenerative cell lineage. Dig Dis Sci, 2003, 48: 2153-2158
11 Meining A, Morgner A, Miehlke S, et al. Atrophy- metaplasia - dysplasiacarcinoma sequence in the stomach: a reality ormerely an hypothesis? Best Pract Res Clin Gastroenterol, 2001, 15: 983-998
12 Kuipers EJ, Uyterlinde AM, Pena AS, et a1. Long-term sequelas of Helicobacter pylori gastritis. Lancet, 1995, 345(8964): 1525-1528
13中华医学会消化病分会·中国慢性胃炎共识意见(2006年,上海)中华消化杂志2007,1(27): 45-50
14江苏新医学院.《中药大辞典》.上海:上海科学技术出版社, 1986: 754-755
15王刚,董枚.半枝莲醇提物抗肿瘤活性的研究.现代中西医结合杂志, 2004, 13(9): 1141-1143
16 Lee T K, Lee D K, Kim D I. Inhibitory effects of Scutellaria barbataD.Don on human uterine leiomy-omal smooth muscle cell proliferation through cell cycle analysis. International Immunopharmacology, 2004, 4(3): 447-454
17董伟华,孔天翰,韩雪飞,等.蝎毒抗癌多肽对4种人肿瘤细胞系的作用.河南医科大学学报, 1999,34(1):52
18中华医学会消化病学分会·幽门螺杆菌共识意见(2003·安徽桐城).中华消化杂志, 2004, 24(2): 126
19张琳.幽门螺杆菌与慢性萎缩性胃炎防治研究.中医杂志,1992,33(7): 27
20李佃贵,赵玉斌,顾洁,等.解毒化浊和胃方阻断大鼠CAG胃癌前病变的分子生物学机制.世界中西医结合杂志, 2006, 1(1): 16
1杨清明,陈丽贞.细胞凋亡及其在肿瘤学的意义.中国肿瘤临床与康复,1997, 4:1-4
2 Farroew S N, White J H, Martinou I, et al. Cloning of a Bcl-2 homologue by interaction with adenovirus EIB19K. Nature,1995,374 (6524):731-733.
3林静,王超,庞有成,等. Bcl-2家族相关基因蛋白在胃癌组织中的表达及意义.中国肿瘤临床与康复,2000, 7(6): 46-48
4张俊峰.雷帕霉素诱导人肝癌细胞BEL-7402凋亡中Bcl-2作用研究.中华肿瘤防治杂志,2006,13(19): 1145-1148
5 Lam M, Dubyad G, Chen L, et al. Evidence that bcl-2 re-press apoptosis by regulating endoplasmic reticulum-associat, 2000, 23 (2): 158-163
6魏玮,史海霞,来要良.中医对慢性萎缩性胃炎及胃癌癌前病变的研究概况.中华中医药杂志,2008,23 (2): 151-154
7李佃贵,赵玉斌,顾洁,等.解毒化浊和胃方阻断大鼠CAG胃癌前病变的分子生物学机制.世界中西医结合杂志, 2006, 1(1): 16-18
8钟秀宏.桦褐孔菌提取物抑制人胃癌BGC-823细胞株增殖及诱导凋亡的实验研究.延边大学, 2006
9孙秀娣,牧人,周有尚,等.中国胃癌死亡率20年变化情况分析及其发展趋势预测.中华肿瘤杂志, 2004, 26(1): 4-9
10杨清明,陈丽贞.细胞凋亡及其在肿瘤学的意义.中国肿瘤临床与康复.1997, 4(3): 1-4
11 Ishii HH, Gobe GC,Pan W, et al. Apoptosis and cell proliferation in the development of gastric carcinomas: associations with c-myc and P53 protein expression. J Gastroenterol Hepatol, 2002,17(9): 966-972
12 Tsujimoto Y, Cossman J, Jaffe E,et al. Involvement of thebcl-2 gene in human follicular lymphoma. Science,1985, 228 (4706): 1440-1443.
13向廷秀,陶小红.槲皮素对BGC-823胃癌细胞p53、Bcl-2/Bax、PCNA表达影响与抑癌作用研究.激光杂志,2006,27(1): 134-136
14 Susin S A, Zamzami N, Castedo M,et al. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. Exp Med, 1996, 184(4): 1331-1341.
15 Oltvai Z N, Milliman CL, Korsmeyer S J. Bcl-2 heterodimerizesin vivowith a conserved homolog, bax, that accelerates programmed cell death. Cell, 1993, 74(4): 609-619
16 Rosse T, Olivier R, Monney L,et al. Bcl-2 prolongs cell survival after bax-induced release of cytochromec. Nature, 1998, 391(6666): 496-499
17 Jurgensmeier J M, Xie Z, Deveraux Q,et al. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA, 2001, 251: 45-52
18 Tsujimolo Y, Shimizu S. Bcl-2 family:life-or-death switch. FEBS Lett. 2000, 466(1): 6-18
19章静波,林建银,杨恬.医学分子细胞生物学.中国协和医科大学出版社,2002:210
20 AlhasanSA, Ensley JF, SarkarFH. Genistein induced molecular changes ina sqmaous cell carcinoma of the head and neck cell line.int J Oncol, 2000, 16: 333-338
21夏荣龙,郑兰东,刘青光,等.丹参对大鼠肝癌恶性梗阻性黄疸时肝癌发展的影响.郑州大学学报(医学版),2005, 40(1): 108-110
22索晴,崔立然,刘树民.黄药子及配伍当归后含药血清抗肿瘤作用的研究.中国中医药科技, 2008, 15(2): 113-114
23 Lee H K, Diterpenes from roots of Agastache rugosa and their cytoroxic activities. Saengyak Hakhaechi, 1994, 25(4): 319-327
24魏道智,宁书菊,林文雄.佩兰的研究进展.时珍国医国药,2007, 18(7): 1782-1783
25董岩,王新芳,崔长军,等.茵陈蒿的化学成分和药理作用研究进展.时珍国医国药,2008, 19(4): 123-125
26王光明,周蓉.半夏的中药药理研究进展.中医药导报,2007, 13(2): 97-99
27许红兰.苦参的药理研究进展.现代医药卫生,2008, 24(20): 3066-3067
28王赞滔,黄艳丽,王文静.白花蛇舌草作用于人胃癌细胞BGC-823后端粒酶的定量表达.临床输血与检验,2006,8(2): 116-117
29雅达斌,李少钦.白花蛇舌草激活肿瘤细胞产生超氧化物和激活半胱氨酸天冬氨酸查白酶诱导肿瘤细胞凋亡.中西医结合学报,2006,4(5): 485-489
30张赛丹,方岩雄,陈敏敏,等.几种传说中药中多糖的提取及抗肿瘤活性研究.中药材,2007,30(2): 179-183
31粟君,谭兴,李劲涛,等.半边莲生物碱的提取及其对胃癌细胞的抑制作用.西华师范大学学报,2007, 28(4): 311-313
32王刚,董玫,郭会灿,等.中药半枝莲提取物体外抗肿瘤活性研究.河北中医,2006, 28(9): 701-702
33连小云,暴蕾,路明.全虫抗肿瘤作用研究进展.时珍国医国药,2002, 13(2): 116-117
1高一心,孙涛. 237例老年人胃癌癌前病变随访分析.肿瘤防治杂志. 2001, 8(2): 118-119
2李庭赞,陈志坦,孙丹莉,等. Hp和CagA+Hp与中国人慢性萎缩性胃炎、胃腺癌、消化性溃疡的关系.临床内科杂志, 2001, 18(1): 28-29
3 Suzuki H, Suzuki M, Mori M, et al. Augmented levels of gastric mucosal leucocyte activation by infection with CagA gene-positive H.pylori.J Gastroenterol Hepatol, 1998, 13 (3): 294-300
4 Takata T, Fujimoto S, anzai K, et al. Analysis of the expression of CagAand VacAand the vacuolating activity in 167 isolates from patients witheither peptic ulcer or non-ulcer diseases. Am J Gastroe- nterol, 1998, 93(1): 30-34
5 Orshini B, Ciancio G, Surrenti E, et al. Seralogical detection of CagA positive H.pylori infection in northern Italian population: Its association with peptic ulcer disease. Helicobacter, 1998, 39(1): 15-20
6 Vorobjova T, Nilsson I, Kull K, et al. CagA protein seropositivity in arandom sample of adault population and gastric cancer patients in Estni-a. Eur J Gastroenterol Hepatol, 1998, 10(1): 41-46
7 Correa P. Human gastric carcinogenesis:a multistep and multifactorial process:first American cancer society award lecture on cancer epidemiology and prevention. Cancer Res, 1992, 5(2): 6735
8余宁,黄茂涛,赵悦,等.幽门螺旋杆菌与胆汁反流性胃炎.华人消化杂志, 1998, 6(11): 944
9 Kopanski Z, Cienciala A, Brandys J, et al. The effect of Helicobacter pylori infection and duodeno gastric reflux on the histology of gastricmucosa in peptic ulcers. Folia Med Cracov, 1996,37(12): 3-14
10姒健敏,高敏,曹倩.生长激素及其受体在萎缩性胃炎中的表达及临床意义探讨.中华消化杂志, 2002, 22(8): 499
11 Zylicz M, King FW, Wawrzynow A.Hsp70 interactions with the p53 tumour suppressor protein. EMBO J 2001,20: 4634-4638
12 Quenneville LA, Trotter MJ, Maeda T, et al. p53- dependent regulation of heat shock protein 72. Br J Dermatol , 2002, 146: 786-791
13 Cheng SB, Hong JQ, Wang YH. Expression and significance of heat shock protein 70 and p53 protein in gastric carcinoma. Shiyong Aizheng Zazhi 2000, 15: 241-242
14陈胜良,李雷佳,童菊芳. alkB基因在胃癌和萎缩性胃炎黏膜组织中的表达改变.胃肠病学, 2007, 12(7): 401-404
15马静.活血化瘀法治疗萎缩性胃炎探析.中医药管理杂, 2006,14(8): 61
16蔡春江,李佃贵,裴林.从“浊”“毒”论治慢性萎缩性胃炎.中国中西医结合消化杂志, 2002, 10(1): 40-41
17李佃贵,王燕云,陈炜.解毒化浊法结合微观检测治疗萎缩性胃炎.北京中医药大学学报(中医临床版), 2004, 11(1):7-8
18王彦刚,李佃贵.基于浊毒学说治疗慢性萎缩性胃炎伴肠上皮化生临床疗效观察.中华中医药杂志, 2009, 24(3): 353-355
19张杰,章天寿.从“虚”“毒”“瘀”论治慢性萎缩性胃炎.中国中医基础医学杂志, 2005, 11(1): 44-45
20杨金坤.健脾方治疗胃黏膜上皮异型增生临床与实验研究.上海中医药杂志, 2000, 34(6): 13215.
21王爱云,单兆伟.慢性萎缩性胃炎从瘀血论治.中国中西医结合消化杂志, 2000, 8: 290
22陈志伟.益气活血通络法治疗慢性萎缩性胃炎癌前病变60例临床研究.浙江中医杂志, 2008, 43(10): 559-561.
23吴学苏.刘永年治疗慢性胃病临床经验.时珍国医国药, 2006, 17(6): 71
24潘华峰,王茵萍.健脾法防治胃癌癌前病变与保护胃壁屏障相关性的探讨.中国中医药信息杂志, 2003, 10(8): 5
25张春妮.辨证论治治疗慢性萎缩性胃炎.中国现代药物应用, 2008, 2(24): 77-78
26林一帆,宋福林,邹蕾,等.中西医结合治疗对萎缩性胃炎癌前病变环氧合酶-2蛋白表达及胃黏膜病理改变的影响.中国中西医结合消化杂志, 2008, 16(5): 289-291.
27周华,许运平,全文静.中西医结合治疗慢性萎缩性胃炎68例临床观察.中外健康文摘.医学刊, 2008, 5(1): 124-126
28邓玉宏.中西医结合治疗慢性萎缩性胃炎56例临床观察,中医药导报, 2006, 12(6): 18-19
29项淑英.中西医结合治疗慢性萎缩性胃炎临床观察、实用中西医结合临床, 2007, 7(5): 10
30楼焕进.中药治疗慢性萎缩性胃炎950例观察.浙江中西医结合杂志, 2002, 12(6): 379
31柯莹玲,单兆伟.辨证治疗慢性萎缩性胃炎癌前病变患者78例.上海中医药大学学报, 2005, 19(4): 18-19
32高富贵.慢性萎缩性胃炎中医辨证治疗108例.医学理论与实践, 2004, 17(8): 909-909
33李成霞.辨证治疗萎缩性胃炎60例临床与病理观察.实用中医内科杂志, 2004, 18(2): 119
34黄朝富,胡林山.健胃防癌汤治疗慢性萎缩性胃炎癌前病变.河北中医药学报, 2008, 23(3): 24-25
35卢国群,王福林.祛瘀化痰法治疗萎缩性胃炎伴异型增生35例.吉林中医药, 2008, 28(9): 661-662
36陈英.中药防治慢性萎缩性胃炎癌前病变100例.光明中医, 2005, 20(5): 52
37杨崇河,刘义桥,武本科,等.胃萎汤治疗慢性萎缩性胃炎癌前病变临床述要实用中医药志, 2006, 22(4): 195-196
38王虹.健中解毒化瘀汤治疗慢性萎缩性胃炎癌前病变40例.辽宁中医学院学报, 2005, 7(5): 488-489
39孙玉霞,王瑞莉,贾成文,等.针刺对慢性萎缩性胃炎大鼠血清胃泌素和血浆胃动素水平的影响,陕西中医, 2006, 17(10): 1301-1302
40高希言,任珊,赵欣纪.穴位贴敷对慢性萎缩性胃炎大鼠胃肠激素影响的实验研究.针刺研究, 2006, 31(2): 107-109
41朱海涛.穴位埋线治疗慢性萎缩性胃炎疗效观察.上海针灸杂志,2008,27(12): 11-12
42张勤勤.针刺治疗慢性萎缩性胃炎56例.浙江中医杂志, 1999,34(7): 299
43于君,张锦坤.胃癌变过程ras基因活化和DNA含量的综合研究.中华内科杂志, 1995, 34(11): 739-741
44佟书娟,刘亚平.胃癌、胃黏膜不典型增生和胃炎组织中P185和P21蛋白的表达及其临床意义.临床内科杂志, 2005, 22(7): 460- 462
45王松坡,张存钧,蒋勇,等.“萎胃安”对慢性萎缩性胃炎PCNA, P21 ras表达的影响.上海中医药杂志, 2006, 40(9): 35-36
46赵玉斌,肖颖.李佃贵解毒化浊和胃方阻断大鼠慢性萎缩性胃炎癌前病变的分子生物学机制.疑难病杂志. 2008, 7(1): 30-32
47卓玉珍,袁红梅,王学,等.善胃方对萎缩性胃炎癌前病变患者P16蛋白的影响.天津中医药, 2006, 23(1): 61-62
48胡玲劳,绍贤,王建华.胃炎消对胃癌癌前病变bcl-2癌基因mRNA表达的影响.上海中医药杂志, 2006, 40(1): 27-28
49常东,努绍贤,樊亚巍.胃炎消对胃癌癌前病变患者P16, Cyclin1Dl, pRb基因蛋白表达的影响.中国中西医结合消化杂志, 2002, 10(5): 277-278
1蔡春江,李佃贵,裴林.“浊”“毒”论治慢性萎缩性胃炎.中国中西医结合消化杂志, 2002, 10(1): 40-41
2吴深涛.论浊毒与糖尿病糖毒性和脂毒性的相关性.中医杂志, 2004, 45(9): 617-619
3刘毅,管竞环.慢性肾衰“毒邪”中医证治探讨.江苏中医药, 2002, 23(11): 52-54
4李佃贵,李海滨,裴林,等.慢性萎缩性胃炎从浊毒论治.四川中医, 2004, 22(1): 17-18
5裴林,李佃贵,蔡春江,等.增生消胶囊对大鼠慢性萎缩性胃炎的防治作用研究.中成药,2003, 25(7): 567-569
6裴林,扈国杰,蔡春江,等.以浊毒理论组方的增生消胶囊治疗慢性萎缩性胃炎癌前病变的临床研究.中国中西医结合消化杂志, 9(3): 168-169
7李佃贵,赵玉斌,顾洁,等.解毒化浊和胃方阻断大鼠慢性萎缩性胃炎癌前病变的分子生物学机制.世界中西医结合杂志,2006, 1(1):16-18
8王彦刚,李佃贵.基于浊毒学说治疗慢性萎缩性胃炎伴肠上皮化生临床疗效观察.中华中医药杂志,2009,24(3): 353-355
9李佃贵,白亚平,吕金仓,等.化浊降逆法治疗功能性消化不良的临床研究.河北中医, 2004, 26(2): 92-94
10李佃贵,白亚平,吕金仓,等.化浊降逆法治疗非溃疡性消化不良的实验研究.中华实用中西医结合杂志,2003, 3(16): 1889-1890
11李佃贵,王静,李瑞东,等.化浊降逆法对胃溃疡大鼠胃组织形态及血清NO血浆ET PAF含量的影响.河北职工医学院学报, 2005, 22(1): 1-3
12李佃贵,李瑞东,李晓荟,等.解毒化浊法治疗溃疡性结肠炎120例临床观察.河北职工医学院学报2005, 22(4):22-23
13王珏,黄学亮,赵红利.李佃贵教授治疗乙型肝炎后肝纤维化经验.河北中医,2004,26(12): 889
14李佃贵,蔡春江,裴林.解毒化浊法治疗慢性乙型肝炎658例.陕西中医,2002, 23(7): 593-594
15王钰,裴林,周英,等.藿香、白芍复方逆转慢性肝纤维化的从浊毒论治的效果.中国临床康复,2006, 10(43): 108-111
16李佃贵,李刚,刘金里.李佃贵以“浊毒”立论治疗肝硬化经验.陕西中医,2006,27(11): 1394-1395
17吴深涛.糖尿病病机的启变要素-浊毒.上海中医药大学学报, 2004, l8(1) :24-26
18阳晓,朱文蜂,周小舟,等.慢性肾衰患者不同阶段病机证候特点临床分析.中医杂志,2000, 14(6): 350
19庚及弟.慢性肾衰脂质肾毒性与中医浊毒病机相关性研究.中国中医药信息杂志,2001, 8(1): 13-14
20焦敏芳,喻红.温阳通腑降浊法治疗慢性肾衰竭阳虚浊毒证疗效观察.湖南中医学院学报,2001, 21(2): 51-52
21张瑞彬.痛风性关节炎中医治疗体会.山东中医杂志, 2003, 22(7): 413-414
22刘存志,于建春.试述韩景献对老年期痴呆基本病机的认识-肾虚痰瘀浊毒论.湖北中医杂志,2004, 26(1): l5-16
2王建华,王晓贞,王顺道.中医证候学研究的思路和方法.北京中医药大学学报, 1999, 4(22): 13-15
3白云静,申洪波,孟庆刚.中医证候复杂性特征及证候研究思路探析.中国中医药信息杂志, 2004, 9(11): 754-756
4李梢.从维度与阶度探讨中医证候的特征及标准化方法.北京中医药大学学报, 2003, 3(26): 1-4
5中华医学会消化病学分会.全国慢性胃炎研讨会共识意见.胃肠病学, 2000, 5(2): 77-79
6中国中西医结合学会消化系统疾病专业委员会.慢性胃炎的中西医结合诊治方案(草案).中国中西医结合杂志, 2005, 25(2): 172-175
7郑筱萸.中药新药临床研究指导原则(试行).北京:中国医药科技出版社, 2002: 124-129
8李乾构,周学文,单兆伟.中华中医药学会脾胃病分会·中医消化病诊疗指南,北京:中国中医药出版社, 2006, 21
9姚乃礼,朱建贵,高荣林.中医证候鉴别诊断学.北京:人民卫生出版社, 2006:2
10国家技术监督局.中医临床诊疗术语·证候部分,北京:中国标准出版社,1997年,第1版: 23
11朱文峰.中医诊断学.北京:中国中医药出版社,1997: 340
12蔡江,李佃贵,裴林.从“浊”“毒”论治慢性萎缩性胃炎.中国中西医结合消化杂志, 2002, 10(1): 41
13李佃贵,李海滨,裴林,等.慢性萎缩性胃炎从浊毒论治.四川中医,2004,22(1):17-18
14胡立胜,周强.中医临床研究设计与SAS编程统计分析.北京:学苑出版社, 2004: 68-79
15董建华,田德禄,麻仲学,等.虚痞中药治疗观察.中国医药学报, 1989, 4: 412
16邢士杰,鞠洪捷.萎缩性胃炎60例辨证治疗和病理观察.中医药信息, 2000, 17(3): 29
17高富贵.慢性萎缩性胃炎中医辨证治疗108例.医学理论与实践, 2004, 17(8): 909
18陈良金.慢性萎缩性胃炎辨证分型与证候特点探析.时珍国医国药, 2005, 16(11): 1149.
19柯莹玲,单兆伟. 542例慢性萎缩性胃炎患者中医辨证分型与病因分析.辽宁中医杂志, 2006, 32(2): 161
20谢晶日,刘磊,李贺薇,等.慢性萎缩性胃炎的中医药研究概况时珍国医国药, 2008, 9(18): 2157-2158
21孙振球,徐勇勇.医学统计学.北京:人民卫生出版社, 2002, 1: 399
1高一心,孙涛. 237例老年人胃癌癌前病变随访分析.肿瘤防治杂志. 2001, 8(2): 118-119
2张学庸,张忠兵,陈希陶,等.萎缩性胃炎胃窦G细胞、组织胃泌素、胃液和血清胃泌素关系初步观察.中华消化杂志, 1984, 4(6): 6-7
3邱泽安,吴晓黎,孔德明,等.胃脘痛脾胃虚弱、脾胃湿热证与4种胃肠激素的变化及意义.亚太传统医药, 2007, 3(8): 28-31
4马艳君,黄岑汉.慢性胃炎中医辨证分型与血清胃泌素和胃动素表达相关性研究.现代中西医结合杂志, 2007, 16(33):4914-4916
5张万岱,智发朝,宋于刚.脾虚证患者血浆、胃液及胃窦十二指肠粘膜胃泌素含量的研究.新消化病学杂志, 1993, 1(特1):14-15
6中华医学会消化病学分会.全国慢性胃炎研讨会共识意见.胃肠病学,2000,5(2):77-79
7中国中西医结合学会消化系统疾病专业委员会.慢性胃炎的中西医结合诊治方案(草案).中国中西医结合杂志, 2005, 25(2): 172-175
8郑筱萸.中药新药临床研究指导原则(试行).北京:中国医药科技出版社, 2002: 124-129
9李乾构,周学文,单兆伟.中医消化病诊疗指南.北京:中国中医药出版社, 2006: 21
10蔡江,李佃贵,裴林.从“浊”“毒”论治慢性萎缩性胃炎.中国中西医结合消化杂志, 2002, 10(1): 41
11李佃贵,李海滨,裴林,等.慢性萎缩性胃炎从浊毒论治.四川中医,2004,22(1):17-18
12姚乃礼,朱建贵,高荣林.中医证候鉴别诊断学.北京:人民卫生出版社, 2006年,第2版: 316
13国家技术监督局.中医临床诊疗术语·证候部分,北京:中国标准出版社,1997年,第1版: 23
14孙凤蓬.胃泌素及其相关胃肠激素的研究进展.国外医学·生理、病理科学与临床分册, 2000, 20(3): 229
15陈智颖,徐鸰鸽,张恩民.慢性多灶萎缩性胃炎患者胃酸分泌与幽门螺杆菌感染及血清胃泌素的关系.临床内科杂志, 2008, 25(8): 523-526
16姚永莉,徐波,宋于刚,等.胃肠道功能紊乱与胃动素关系的实验研究.第一军医大学学报, 2001, 21(8): 602-603
17李红涛,吴开春,李彩宁,等.血清胃泌素对老年人慢性萎缩性胃炎的诊断.中华老年医学杂志. 2004, 23(4): 238
18田德禄.中医内科学.北京:人民卫生出版社, 2003, 177
19 Poitras P, Dumont A, Cuber JC, Boivin M and Trudel L. Cholinergicregulation of motilin release from isolated canine intestinal cells. Regulatory Peptides, 1992, 40: 30
20 Ryouichi T, Shigeru F, Katsuhisa T and Masahiro F. Studies on gastrointestinal hormone and jejunal interdigestive migrating motor complex in patients with or without early dumping syndrome after total gastrectomy with Roux-en-Y reconstruction for early gastric cancer. The American Journal of Surgery, 2003, 185, 354-59
21 K.Milenov and A.Shahbazian.Cholinergic pathways in the effect of motilin on the canine ileum and gallbladder motility:in vivo and in vitro experiments, Comparative Biochemistry and Physiology Part A: Physiology, 1995, 112: 403-410
22张锦坤,肖澎荣,吴紫霞,等.胃运动功能的研究.中华消化杂志, 1984, 4(4): 233
23陈方元.胃肠激素与胃肠运动.国外医学·消化系统疾病分册, 1992, 12: 2-6
24许昌泰,王奕,潘伯荣.萎缩性胃炎患者血清胃液脑肠肽的研究.新消化病学杂志, 1997, 5(11): 713
25高希言,任珊,赵欣纪.穴位贴敷对慢性萎缩性胃炎大鼠胃肠激素影响的实验研究.针刺研究, 2006, 31(2): 107-109
26孙凤蓬,宋于刚,覃汉荣.胃溃疡大鼠胃泌素、生长抑素和G、D细胞的变化.世界华人消化杂志. 2004, 12: 363-366
27李秋娟,仲来福,叶建新,等.大鼠实验性慢性萎缩性胃炎与胃黏膜生长抑素、胃泌素关系的研究.大连医科大学学报, 1999, 21: 89-91
1李乾构,周学文,单兆伟.中华中医药学会脾胃病分会·中医消化病诊疗指南.北京:中国中医药出版社, 2006:21
2 Correa P.A human model of gastric carcinogenesis. Cancer Res, 1988, 48: 3554-3560
3 Tatem atsu M, Tsukamoto T, Inada K. Stem cells and gastric cancer role of gastric and intestinal mixed intestinal metaplasia. Cancer Sci, 2003, 9(4):135-141
4中华医学会消化病学分会.全国慢性胃炎研讨会共识意见.胃肠病学,2000, 5(2): 77-79
5蔡江,李佃贵,裴林.从“浊”“毒”论治慢性萎缩性胃炎.中国中西医结合消化杂志.2002,10(1): 41
6郑筱萸.中药新药临床研究指导原则(试行).北京:中国医药科技出版社, 2002: 124-129
7中华医学会消化内镜学分会2003年《慢性胃炎的内镜分型分级标准及治疗的试行意见》.中华消化内镜杂志, 2004, 21(2)::77-78
8劳绍贤.胃癌癌前病变的基础与临床.广州:广东人民出版社, 2002:193
9中华医学会消化病学分会.幽门螺杆菌共识意见(2003·安徽桐城).胃肠病学, 2004, 9 (1):46-47
10 Mukaisho K, Miwa K, Kumagai H, et al. Gastric carcinogenesis by duodenal reflux through gut regenerative cell lineage. Dig Dis Sci, 2003, 48: 2153-2158
11 Meining A, Morgner A, Miehlke S, et al. Atrophy- metaplasia - dysplasiacarcinoma sequence in the stomach: a reality ormerely an hypothesis? Best Pract Res Clin Gastroenterol, 2001, 15: 983-998
12 Kuipers EJ, Uyterlinde AM, Pena AS, et a1. Long-term sequelas of Helicobacter pylori gastritis. Lancet, 1995, 345(8964): 1525-1528
13中华医学会消化病分会·中国慢性胃炎共识意见(2006年,上海)中华消化杂志2007,1(27): 45-50
14江苏新医学院.《中药大辞典》.上海:上海科学技术出版社, 1986: 754-755
15王刚,董枚.半枝莲醇提物抗肿瘤活性的研究.现代中西医结合杂志, 2004, 13(9): 1141-1143
16 Lee T K, Lee D K, Kim D I. Inhibitory effects of Scutellaria barbataD.Don on human uterine leiomy-omal smooth muscle cell proliferation through cell cycle analysis. International Immunopharmacology, 2004, 4(3): 447-454
17董伟华,孔天翰,韩雪飞,等.蝎毒抗癌多肽对4种人肿瘤细胞系的作用.河南医科大学学报, 1999,34(1):52
18中华医学会消化病学分会·幽门螺杆菌共识意见(2003·安徽桐城).中华消化杂志, 2004, 24(2): 126
19张琳.幽门螺杆菌与慢性萎缩性胃炎防治研究.中医杂志,1992,33(7): 27
20李佃贵,赵玉斌,顾洁,等.解毒化浊和胃方阻断大鼠CAG胃癌前病变的分子生物学机制.世界中西医结合杂志, 2006, 1(1): 16
1杨清明,陈丽贞.细胞凋亡及其在肿瘤学的意义.中国肿瘤临床与康复,1997, 4:1-4
2 Farroew S N, White J H, Martinou I, et al. Cloning of a Bcl-2 homologue by interaction with adenovirus EIB19K. Nature,1995,374 (6524):731-733.
3林静,王超,庞有成,等. Bcl-2家族相关基因蛋白在胃癌组织中的表达及意义.中国肿瘤临床与康复,2000, 7(6): 46-48
4张俊峰.雷帕霉素诱导人肝癌细胞BEL-7402凋亡中Bcl-2作用研究.中华肿瘤防治杂志,2006,13(19): 1145-1148
5 Lam M, Dubyad G, Chen L, et al. Evidence that bcl-2 re-press apoptosis by regulating endoplasmic reticulum-associat, 2000, 23 (2): 158-163
6魏玮,史海霞,来要良.中医对慢性萎缩性胃炎及胃癌癌前病变的研究概况.中华中医药杂志,2008,23 (2): 151-154
7李佃贵,赵玉斌,顾洁,等.解毒化浊和胃方阻断大鼠CAG胃癌前病变的分子生物学机制.世界中西医结合杂志, 2006, 1(1): 16-18
8钟秀宏.桦褐孔菌提取物抑制人胃癌BGC-823细胞株增殖及诱导凋亡的实验研究.延边大学, 2006
9孙秀娣,牧人,周有尚,等.中国胃癌死亡率20年变化情况分析及其发展趋势预测.中华肿瘤杂志, 2004, 26(1): 4-9
10杨清明,陈丽贞.细胞凋亡及其在肿瘤学的意义.中国肿瘤临床与康复.1997, 4(3): 1-4
11 Ishii HH, Gobe GC,Pan W, et al. Apoptosis and cell proliferation in the development of gastric carcinomas: associations with c-myc and P53 protein expression. J Gastroenterol Hepatol, 2002,17(9): 966-972
12 Tsujimoto Y, Cossman J, Jaffe E,et al. Involvement of thebcl-2 gene in human follicular lymphoma. Science,1985, 228 (4706): 1440-1443.
13向廷秀,陶小红.槲皮素对BGC-823胃癌细胞p53、Bcl-2/Bax、PCNA表达影响与抑癌作用研究.激光杂志,2006,27(1): 134-136
14 Susin S A, Zamzami N, Castedo M,et al. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. Exp Med, 1996, 184(4): 1331-1341.
15 Oltvai Z N, Milliman CL, Korsmeyer S J. Bcl-2 heterodimerizesin vivowith a conserved homolog, bax, that accelerates programmed cell death. Cell, 1993, 74(4): 609-619
16 Rosse T, Olivier R, Monney L,et al. Bcl-2 prolongs cell survival after bax-induced release of cytochromec. Nature, 1998, 391(6666): 496-499
17 Jurgensmeier J M, Xie Z, Deveraux Q,et al. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA, 2001, 251: 45-52
18 Tsujimolo Y, Shimizu S. Bcl-2 family:life-or-death switch. FEBS Lett. 2000, 466(1): 6-18
19章静波,林建银,杨恬.医学分子细胞生物学.中国协和医科大学出版社,2002:210
20 AlhasanSA, Ensley JF, SarkarFH. Genistein induced molecular changes ina sqmaous cell carcinoma of the head and neck cell line.int J Oncol, 2000, 16: 333-338
21夏荣龙,郑兰东,刘青光,等.丹参对大鼠肝癌恶性梗阻性黄疸时肝癌发展的影响.郑州大学学报(医学版),2005, 40(1): 108-110
22索晴,崔立然,刘树民.黄药子及配伍当归后含药血清抗肿瘤作用的研究.中国中医药科技, 2008, 15(2): 113-114
23 Lee H K, Diterpenes from roots of Agastache rugosa and their cytoroxic activities. Saengyak Hakhaechi, 1994, 25(4): 319-327
24魏道智,宁书菊,林文雄.佩兰的研究进展.时珍国医国药,2007, 18(7): 1782-1783
25董岩,王新芳,崔长军,等.茵陈蒿的化学成分和药理作用研究进展.时珍国医国药,2008, 19(4): 123-125
26王光明,周蓉.半夏的中药药理研究进展.中医药导报,2007, 13(2): 97-99
27许红兰.苦参的药理研究进展.现代医药卫生,2008, 24(20): 3066-3067
28王赞滔,黄艳丽,王文静.白花蛇舌草作用于人胃癌细胞BGC-823后端粒酶的定量表达.临床输血与检验,2006,8(2): 116-117
29雅达斌,李少钦.白花蛇舌草激活肿瘤细胞产生超氧化物和激活半胱氨酸天冬氨酸查白酶诱导肿瘤细胞凋亡.中西医结合学报,2006,4(5): 485-489
30张赛丹,方岩雄,陈敏敏,等.几种传说中药中多糖的提取及抗肿瘤活性研究.中药材,2007,30(2): 179-183
31粟君,谭兴,李劲涛,等.半边莲生物碱的提取及其对胃癌细胞的抑制作用.西华师范大学学报,2007, 28(4): 311-313
32王刚,董玫,郭会灿,等.中药半枝莲提取物体外抗肿瘤活性研究.河北中医,2006, 28(9): 701-702
33连小云,暴蕾,路明.全虫抗肿瘤作用研究进展.时珍国医国药,2002, 13(2): 116-117
1高一心,孙涛. 237例老年人胃癌癌前病变随访分析.肿瘤防治杂志. 2001, 8(2): 118-119
2李庭赞,陈志坦,孙丹莉,等. Hp和CagA+Hp与中国人慢性萎缩性胃炎、胃腺癌、消化性溃疡的关系.临床内科杂志, 2001, 18(1): 28-29
3 Suzuki H, Suzuki M, Mori M, et al. Augmented levels of gastric mucosal leucocyte activation by infection with CagA gene-positive H.pylori.J Gastroenterol Hepatol, 1998, 13 (3): 294-300
4 Takata T, Fujimoto S, anzai K, et al. Analysis of the expression of CagAand VacAand the vacuolating activity in 167 isolates from patients witheither peptic ulcer or non-ulcer diseases. Am J Gastroe- nterol, 1998, 93(1): 30-34
5 Orshini B, Ciancio G, Surrenti E, et al. Seralogical detection of CagA positive H.pylori infection in northern Italian population: Its association with peptic ulcer disease. Helicobacter, 1998, 39(1): 15-20
6 Vorobjova T, Nilsson I, Kull K, et al. CagA protein seropositivity in arandom sample of adault population and gastric cancer patients in Estni-a. Eur J Gastroenterol Hepatol, 1998, 10(1): 41-46
7 Correa P. Human gastric carcinogenesis:a multistep and multifactorial process:first American cancer society award lecture on cancer epidemiology and prevention. Cancer Res, 1992, 5(2): 6735
8余宁,黄茂涛,赵悦,等.幽门螺旋杆菌与胆汁反流性胃炎.华人消化杂志, 1998, 6(11): 944
9 Kopanski Z, Cienciala A, Brandys J, et al. The effect of Helicobacter pylori infection and duodeno gastric reflux on the histology of gastricmucosa in peptic ulcers. Folia Med Cracov, 1996,37(12): 3-14
10姒健敏,高敏,曹倩.生长激素及其受体在萎缩性胃炎中的表达及临床意义探讨.中华消化杂志, 2002, 22(8): 499
11 Zylicz M, King FW, Wawrzynow A.Hsp70 interactions with the p53 tumour suppressor protein. EMBO J 2001,20: 4634-4638
12 Quenneville LA, Trotter MJ, Maeda T, et al. p53- dependent regulation of heat shock protein 72. Br J Dermatol , 2002, 146: 786-791
13 Cheng SB, Hong JQ, Wang YH. Expression and significance of heat shock protein 70 and p53 protein in gastric carcinoma. Shiyong Aizheng Zazhi 2000, 15: 241-242
14陈胜良,李雷佳,童菊芳. alkB基因在胃癌和萎缩性胃炎黏膜组织中的表达改变.胃肠病学, 2007, 12(7): 401-404
15马静.活血化瘀法治疗萎缩性胃炎探析.中医药管理杂, 2006,14(8): 61
16蔡春江,李佃贵,裴林.从“浊”“毒”论治慢性萎缩性胃炎.中国中西医结合消化杂志, 2002, 10(1): 40-41
17李佃贵,王燕云,陈炜.解毒化浊法结合微观检测治疗萎缩性胃炎.北京中医药大学学报(中医临床版), 2004, 11(1):7-8
18王彦刚,李佃贵.基于浊毒学说治疗慢性萎缩性胃炎伴肠上皮化生临床疗效观察.中华中医药杂志, 2009, 24(3): 353-355
19张杰,章天寿.从“虚”“毒”“瘀”论治慢性萎缩性胃炎.中国中医基础医学杂志, 2005, 11(1): 44-45
20杨金坤.健脾方治疗胃黏膜上皮异型增生临床与实验研究.上海中医药杂志, 2000, 34(6): 13215.
21王爱云,单兆伟.慢性萎缩性胃炎从瘀血论治.中国中西医结合消化杂志, 2000, 8: 290
22陈志伟.益气活血通络法治疗慢性萎缩性胃炎癌前病变60例临床研究.浙江中医杂志, 2008, 43(10): 559-561.
23吴学苏.刘永年治疗慢性胃病临床经验.时珍国医国药, 2006, 17(6): 71
24潘华峰,王茵萍.健脾法防治胃癌癌前病变与保护胃壁屏障相关性的探讨.中国中医药信息杂志, 2003, 10(8): 5
25张春妮.辨证论治治疗慢性萎缩性胃炎.中国现代药物应用, 2008, 2(24): 77-78
26林一帆,宋福林,邹蕾,等.中西医结合治疗对萎缩性胃炎癌前病变环氧合酶-2蛋白表达及胃黏膜病理改变的影响.中国中西医结合消化杂志, 2008, 16(5): 289-291.
27周华,许运平,全文静.中西医结合治疗慢性萎缩性胃炎68例临床观察.中外健康文摘.医学刊, 2008, 5(1): 124-126
28邓玉宏.中西医结合治疗慢性萎缩性胃炎56例临床观察,中医药导报, 2006, 12(6): 18-19
29项淑英.中西医结合治疗慢性萎缩性胃炎临床观察、实用中西医结合临床, 2007, 7(5): 10
30楼焕进.中药治疗慢性萎缩性胃炎950例观察.浙江中西医结合杂志, 2002, 12(6): 379
31柯莹玲,单兆伟.辨证治疗慢性萎缩性胃炎癌前病变患者78例.上海中医药大学学报, 2005, 19(4): 18-19
32高富贵.慢性萎缩性胃炎中医辨证治疗108例.医学理论与实践, 2004, 17(8): 909-909
33李成霞.辨证治疗萎缩性胃炎60例临床与病理观察.实用中医内科杂志, 2004, 18(2): 119
34黄朝富,胡林山.健胃防癌汤治疗慢性萎缩性胃炎癌前病变.河北中医药学报, 2008, 23(3): 24-25
35卢国群,王福林.祛瘀化痰法治疗萎缩性胃炎伴异型增生35例.吉林中医药, 2008, 28(9): 661-662
36陈英.中药防治慢性萎缩性胃炎癌前病变100例.光明中医, 2005, 20(5): 52
37杨崇河,刘义桥,武本科,等.胃萎汤治疗慢性萎缩性胃炎癌前病变临床述要实用中医药志, 2006, 22(4): 195-196
38王虹.健中解毒化瘀汤治疗慢性萎缩性胃炎癌前病变40例.辽宁中医学院学报, 2005, 7(5): 488-489
39孙玉霞,王瑞莉,贾成文,等.针刺对慢性萎缩性胃炎大鼠血清胃泌素和血浆胃动素水平的影响,陕西中医, 2006, 17(10): 1301-1302
40高希言,任珊,赵欣纪.穴位贴敷对慢性萎缩性胃炎大鼠胃肠激素影响的实验研究.针刺研究, 2006, 31(2): 107-109
41朱海涛.穴位埋线治疗慢性萎缩性胃炎疗效观察.上海针灸杂志,2008,27(12): 11-12
42张勤勤.针刺治疗慢性萎缩性胃炎56例.浙江中医杂志, 1999,34(7): 299
43于君,张锦坤.胃癌变过程ras基因活化和DNA含量的综合研究.中华内科杂志, 1995, 34(11): 739-741
44佟书娟,刘亚平.胃癌、胃黏膜不典型增生和胃炎组织中P185和P21蛋白的表达及其临床意义.临床内科杂志, 2005, 22(7): 460- 462
45王松坡,张存钧,蒋勇,等.“萎胃安”对慢性萎缩性胃炎PCNA, P21 ras表达的影响.上海中医药杂志, 2006, 40(9): 35-36
46赵玉斌,肖颖.李佃贵解毒化浊和胃方阻断大鼠慢性萎缩性胃炎癌前病变的分子生物学机制.疑难病杂志. 2008, 7(1): 30-32
47卓玉珍,袁红梅,王学,等.善胃方对萎缩性胃炎癌前病变患者P16蛋白的影响.天津中医药, 2006, 23(1): 61-62
48胡玲劳,绍贤,王建华.胃炎消对胃癌癌前病变bcl-2癌基因mRNA表达的影响.上海中医药杂志, 2006, 40(1): 27-28
49常东,努绍贤,樊亚巍.胃炎消对胃癌癌前病变患者P16, Cyclin1Dl, pRb基因蛋白表达的影响.中国中西医结合消化杂志, 2002, 10(5): 277-278
1蔡春江,李佃贵,裴林.“浊”“毒”论治慢性萎缩性胃炎.中国中西医结合消化杂志, 2002, 10(1): 40-41
2吴深涛.论浊毒与糖尿病糖毒性和脂毒性的相关性.中医杂志, 2004, 45(9): 617-619
3刘毅,管竞环.慢性肾衰“毒邪”中医证治探讨.江苏中医药, 2002, 23(11): 52-54
4李佃贵,李海滨,裴林,等.慢性萎缩性胃炎从浊毒论治.四川中医, 2004, 22(1): 17-18
5裴林,李佃贵,蔡春江,等.增生消胶囊对大鼠慢性萎缩性胃炎的防治作用研究.中成药,2003, 25(7): 567-569
6裴林,扈国杰,蔡春江,等.以浊毒理论组方的增生消胶囊治疗慢性萎缩性胃炎癌前病变的临床研究.中国中西医结合消化杂志, 9(3): 168-169
7李佃贵,赵玉斌,顾洁,等.解毒化浊和胃方阻断大鼠慢性萎缩性胃炎癌前病变的分子生物学机制.世界中西医结合杂志,2006, 1(1):16-18
8王彦刚,李佃贵.基于浊毒学说治疗慢性萎缩性胃炎伴肠上皮化生临床疗效观察.中华中医药杂志,2009,24(3): 353-355
9李佃贵,白亚平,吕金仓,等.化浊降逆法治疗功能性消化不良的临床研究.河北中医, 2004, 26(2): 92-94
10李佃贵,白亚平,吕金仓,等.化浊降逆法治疗非溃疡性消化不良的实验研究.中华实用中西医结合杂志,2003, 3(16): 1889-1890
11李佃贵,王静,李瑞东,等.化浊降逆法对胃溃疡大鼠胃组织形态及血清NO血浆ET PAF含量的影响.河北职工医学院学报, 2005, 22(1): 1-3
12李佃贵,李瑞东,李晓荟,等.解毒化浊法治疗溃疡性结肠炎120例临床观察.河北职工医学院学报2005, 22(4):22-23
13王珏,黄学亮,赵红利.李佃贵教授治疗乙型肝炎后肝纤维化经验.河北中医,2004,26(12): 889
14李佃贵,蔡春江,裴林.解毒化浊法治疗慢性乙型肝炎658例.陕西中医,2002, 23(7): 593-594
15王钰,裴林,周英,等.藿香、白芍复方逆转慢性肝纤维化的从浊毒论治的效果.中国临床康复,2006, 10(43): 108-111
16李佃贵,李刚,刘金里.李佃贵以“浊毒”立论治疗肝硬化经验.陕西中医,2006,27(11): 1394-1395
17吴深涛.糖尿病病机的启变要素-浊毒.上海中医药大学学报, 2004, l8(1) :24-26
18阳晓,朱文蜂,周小舟,等.慢性肾衰患者不同阶段病机证候特点临床分析.中医杂志,2000, 14(6): 350
19庚及弟.慢性肾衰脂质肾毒性与中医浊毒病机相关性研究.中国中医药信息杂志,2001, 8(1): 13-14
20焦敏芳,喻红.温阳通腑降浊法治疗慢性肾衰竭阳虚浊毒证疗效观察.湖南中医学院学报,2001, 21(2): 51-52
21张瑞彬.痛风性关节炎中医治疗体会.山东中医杂志, 2003, 22(7): 413-414
22刘存志,于建春.试述韩景献对老年期痴呆基本病机的认识-肾虚痰瘀浊毒论.湖北中医杂志,2004, 26(1): l5-16